Western Michigan University

ScholarWorks at WMU
Dissertations

Graduate College

6-2017

Discriminative and Reinforcing Effects of Cocaine-Levamisole
Combinations
Zachary J. Zimmermann
Western Michigan University, zimmermanzj@yahoo.com

Follow this and additional works at: https://scholarworks.wmich.edu/dissertations
Part of the Substance Abuse and Addiction Commons

Recommended Citation
Zimmermann, Zachary J., "Discriminative and Reinforcing Effects of Cocaine-Levamisole Combinations"
(2017). Dissertations. 3120.
https://scholarworks.wmich.edu/dissertations/3120

This Dissertation-Open Access is brought to you for free
and open access by the Graduate College at
ScholarWorks at WMU. It has been accepted for inclusion
in Dissertations by an authorized administrator of
ScholarWorks at WMU. For more information, please
contact wmu-scholarworks@wmich.edu.

DISCRIMINATIVE AND REINFORCING EFFECTS OF COCAINE-LEVAMISOLE
COMBINATIONS

by
Zachary J. Zimmermann

A dissertation submitted to the Graduate College
in partial fulfillment of the requirements
for the degree of Doctor of Philosophy
Psychology
Western Michigan University
June 2017

Dissertation Committee:
Alan Poling, Ph.D., Chair
Lisa Baker, Ph.D.
David V. Gauvin, Ph.D.
Cynthia Pietras, Ph.D.

DISCRIMINATIVE AND REINFORCING EFFECTS OF COCAINE-LEVAMISOLE
COMBINATIONS

Zachary J. Zimmermann, Ph.D.
Western Michigan University, 2017

The behavioral and neurochemical effects of cocaine are well established, and it is one of the
most widely abused illicit drugs. Illicit cocaine is often adulterated with levamisole, which is an
anthelmintic that was withdrawn from the U. S. market in 2000. It has been hypothesized that
levamisole, unlike other common adulterants which are added as simple bulking agents, has
effects of its own which may be responsible for its use as an adulterant. Although these effects
are speculative, the addition of levamisole to cocaine has become an increasing public health
concern, as serious adverse effects (e.g., vasculitis, neutropenia) of levamisole-adulterated
cocaine have been observed in drug users.
The present experiments were intended to provide further information about effects of
levamisole that may help to explain its use as an adulterant. The aim of the first experiment was
to determine if adding levamisole alters cocaine self-administration in rats. To this end, the
response patterns of rats trained to self-administer cocaine were examined to determine whether
they were altered by pretreatment with two doses of levamisole (1 and 10 mg/kg). Although
response patterns were generally unaffected, animals consistently consumed less cocaine at all
doses tested under both pretreatment conditions. This decrease in responding suggests that
levamisole is not added to directly increase cocaine intake.
The aim of the second experiment was to examine how adding levamisole affected the
discriminative stimulus properties of cocaine. Rats were trained to discriminate between cocaine

and saline injections to earn food in a classic drug discrimination procedure. Various doses of
cocaine, levamisole, and cocaine-levamisole combinations were then tested to yield crossgeneralization profiles. Levamisole alone failed to produce cocaine-appropriate responding in the
majority of animals, but did so in a dose-dependent manner for a small minority. Cocainelevamisole combinations consistently produced dose-dependent cocaine-appropriate responding,
and did so to a greater extent than did the constituent cocaine or levamisole dose alone (i.e.,
supra-additivity).
The results of these studies are consistent with the popular notion that levamisole is
added to cocaine to alter its effects, rather than simply as a bulking agent. Furthermore, these
results indicate that a supra-additive interaction between cocaine and levamisole exists with
regard to their discriminative stimulus effects. Further research into the behavioral and
neurochemical mechanisms of action of cocaine-levamisole combinations is warranted.
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CHAPTER I
INTRODUCTION
General Background
Although most drugs of abuse have been studied extensively within the context of the
available abuse liability paradigms, the compounds employed therein are often of laboratory
grade, and thus do not necessary reflect the true effects of “street drugs”, which contain a number
of other constituents unbeknownst to the consumer. Furthermore, little is known regarding the
combined effects of many common adulterants or bulking agents found in street drugs, many of
which can have profound influence upon the effects of these drugs (Cole et al., 2010).
Levamisole is an increasingly prevalent adulterant reportedly found in illicitly manufactured
cocaine is levamisole (Abdul-Karim, Ryan, Rangel, & Emmett, 2013). Levamisole has a lengthy
history as an anthelmintic for treating parasitic worm infections. However, levamisole was
withdrawn from the U.S. market in 2000 due to a combination of factors relating to adverse
clinical reactions. It has been hypothesized that the rise in levamisole-adulterated cocaine can be
attributed to possible stimulant effects of levamisole itself (Tallarida et al., 2014; Tallarida,
Tallarida, & Rawls, 2015). Though some have cited these stimulant effects as being responsible
for the rise in the incidence of levamisole-adulterated cocaine, little behavioral research has been
conducted directly examining the subjective effects of levamisole-cocaine mixtures and the
subsequent effects upon drug consumption. The aim of the studies described herein was to assess
both of these aspects relevant to human drug taking behavior using established animal models—
self-administration and drug discrimination.
Cocaine
Production and distribution. Illicit drug use and abuse costs the United States more
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than $193 billion annually (National Drug Intelligence Center, 2011). Indeed, the American war
on drugs has been repeatedly declared an utter failure. Though they may disagree on the tactics,
it is the combined goal of law enforcement and policy makers to enact changes that not only
prevent the initiation of drug use by Americans, but also decrease the number of current users.
Drug abuse is a global problem, and dealing with the problem as if the U.S. drug market exists
within a vacuum would be naïve. In light of this, the U.S. has joined numerous international
organizations and alliances to help stop the global trade of illicit drugs, combat the threat of new
drugs, and curtail the crime associated with illicit drug trade and use.
The World Health Organization (WHO) has been tasked with providing expert guidance
to the United Nations on international issues of schedule control and drug abuse prevention
(United Nations, 1988; WHO, 2016). In recent years (2007 to 2012), cocaine availability within
the U.S. has declined. It is believed that these efforts have contributed to the dramatic recent
decreases seen in cocaine use and distribution data. Although it is impossible to infer causation
based on the available sampling metrics alone, both American cocaine use and global coca bush
cultivation have been on the steady decline (United Nations Office on Drugs and Crime
(UNODC), 2015). Cocaine is largely an export from South American countries (e.g., Argentina,
Bolivia, Columbia, Ecuador, and Peru), with the majority of the cocaine originating in Columbia
and entering the U.S. through Mexico, an international border notoriously fraught with
corruption, smuggling, and other illegal activity.
The coca plant (Erythroxylon coca), the source of a drug that has plagued the
international community, has enjoyed a lengthy history in both medicinal and religious activities.
The infamous stimulant properties of the plant have traditionally been produced by a drinkable
preparation (mate de coca, Vin Mariani) or through oral consumption of the leaves (chewing)
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(Stolberg, 2011). Coca leaves contain the cocaine alkaloid that can be chemically extracted to
form coca paste. Through many chemical additions and purifications, coca paste is refined into
powder form (cocaine hydrochloride), the form popularized in today’s drug and media culture.
After being converted into powder form, it is then packaged and is ready for bulk distribution.
Once it has been distributed across the greater U.S. to mid-level drug dealers, it is then generally
mixed with a variety of compounds (i.e., “cut” or “stepped on”), sold to other dealers, and
eventually directly to users. Though cocaine has limited medical use (CII), the primary domestic
consumption of cocaine is of the illicit variety, with 270 tons of illicit cocaine seized in 2014
(UNODC, 2015) compared to the legally-sanctioned production of 200 kg per year (DEA, 2015).
Adulteration and drug manufacturing. Though “cutting” of street drugs with toxic
substances is often the basis of urban legend, the process of adulterating street drugs is a very
real and serious issue that can have a variety of unintended effects on both the drug user and the
drug market. Through dilution of the initial bulk product, street dealers are able to increase their
profit margin while maintaining an initial set cost of investment. Additionally, the notion that
other dealers conduct themselves in the same manner leads to a perpetuation of adulterating
drugs, generating what has been referred to as the “self-fulfilling prophecy” of adulteration
(DeCorte, 2001). Adulterants are also often referred to as cutting/bulking agents or diluents,
though their addition may serve purposes beyond simply increasing the amount of sellable
product. Certain additions to bulk product can either serve to potentiate the effects of the
constituent drug itself, or act to mimic the effects of the relevant drug. One recent example of
street-level adulteration is 3,4-methylenedioxy-methamphetamine (MDMA or “ecstasy”). As has
been extensively documented in both the research literature (Parrott, 2004; Sherlock, Wolff, Hay,
& Conner, 1999) and the popular drug culture (DanceSafe, 2016), ecstasy often contains
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stimulant drugs other than MDMA. Though designer drugs like ecstasy have been notorious
targets for media coverage on drug adulteration, all street drugs, including cocaine and heroin,
are subject to the same diluent processes as their popular designer counterparts.
Pharmacology. Vast amounts of research dollars and resources have been dedicated to
examining the neuropharmacological and behavioral effects of cocaine. It is well established that
the reinforcing effects of cocaine are primarily mediated through the mesolimbic dopamine
system (Callahan, de La Garza, & Cunningham, 1997). In summary, cocaine is a potent small
molecule psychostimulant that readily crosses the blood-brain barrier. Once in the brain, cocaine
binds to the dopamine transporter (DAT), which is responsible for reclaiming dopamine and
decreasing concentrations within the synapse, thus blocking reuptake of dopamine into the nerve
terminal (Cooper, Bloom, & Roth, 2003). Once cocaine has bound to DAT, dopamine rapidly
begins accumulating in the synaptic cleft, increasing extracellular levels of dopamine (Carrera,
Meijer, & Janda, 2004). In this way, cocaine is an indirect-acting dopamine agonist, action that is
distinct from other, direct-acting dopamine agonists that are also common drugs of abuse (e.g.,
amphetamine). Although cocaine does affect other neurotransmitter systems, its reinforcing and
discriminative effects are mediated primarily through dopaminergic activity (Baker, Riddle,
Saunders, & Appel, 1993; Cunningham & Callahan, 1991). Cocaine is a quick-acting stimulant,
with a half-life of approximately 40 min in humans (Fischman, 1984), 18 min in rats (Barbieri,
Ferko, DiGregorio, & Ruch, 1992) and 20-24 min in rhesus monkeys (Saady, Bowman, & Aceto,
1995).
Levamisole
Levamisole was discovered in 1966 by Belgian scientists working at Janssen
Pharmaceutica. In an attempt to develop the next revolutionary anthelmintic drug, Janssen
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created and pursued over 2700 chemicals before finally uncovering the racemate, tetramisole.
Tetramisole consisted of two enantiomers, dexamisole and levamisole. Though tetramisole was
found to be effective in eliminating gastrointenstial nematodes in chickens, further examination
eventually led to separation and development of the safer, more potent isomer levamisole
(Amery & Bruynseels, 1992; Janssen, 1976).
The primary intended use of levamisole was as an anthelmintic and immunomodulator.
During the late 1970s into the 1980s, levamisole enjoyed a skyrocketing popularity in its use and
prescription as a miracle drug for ailments ranging from herpes, leprosy, rheumatoid arthritis,
lupus, and colorectal cancer (Amery & Bruynseels, 1992; Luyckx et al., 1982). It appeared as
though levamisole was a safe and effective treatment for a number of maladies, and it became a
welcome addition to clinician’s tool belts worldwide. However, as prescription use and treatment
became more prevalent, a number of adverse side effects were reported, ranging in severity from
skin discolorations and minor infection to agranulocytosis and leukoencephalopathy. In light of
these clinical findings, levamisole was withdrawn from the U.S. market in 2000 due to a
combination of factors involving: 1) an increased availability of newer, safer replacement drugs,
and 2) an increased prevalence of reports indicating a risk of serious adverse side effects in
humans (e.g., agranulocytosis, vasculitis, and leukoencephalopathy). Currently, levamisole is
used abroad as an anthelminitic in livestock (e.g., sheep, cattle, pigs). Due to the physical and
chemical properties of the drug (i.e., relatively odorless, white powder, high melting point,
limited stimulant-like discriminative stimulus properties, ability to pass common street purity
tests), in addition to its widespread availability in veterinary medicine, it is increasingly being
employed as an adulterant in illicitly manufactured cocaine. Indeed, as recently as 2009, the
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DEA confirmed that over 70% of seized samples tested positive for the presence of levamisole
(Abdul-Karim et al., 2013).
Pharmacology. Although levamisole has an extensive clinical history, its
pharmacological profile regarding the immunomodulatory effects is still incomplete. However, it
has been hypothesized that these effects stem from a combination of the following: 1) restoration
of normalized function to T-lymphocytes and phagocytes, 2) action as a prodrug for 2-oxo-3-(2mercaptoethyl)-5-phenylimidazole (OMPI), 3) blocking the action of natural immunosuppressive
factors (Avery & Bruynseels, 1992; Hodinka, Géher, Merétey, Gyódi, Petrányi, & Bozsóky,
1981), and 4) agonist activity at nicotinic receptors in nematodes (DEA, 2013; Janssen, 1976).
Although the peak plasma concentrations of levamisole in humans occur approximately 1-2 hr
post-dose (Luyckx et al., 1982), the effects of levamisole in other species have been
demonstrated in as little as 30 min post-dose (Tallarida et al., 2014; Tallarida, Tallarida, &
Rawls, 2015).
Levamisole is a nicotinic receptor agonist that readily crosses the blood-brain barrier and
affects dopaminergic activity, resulting in weak stimulant effects (Adams, 1978; JiménezGonzález, Ros-Moreno, Moreno-Guzmán, Rodríguez-Caabeiro, 1999; Hofmaier et al., 2014;
Robertson, Bjorn, & Martin, 1999). Its actions on nicotinic acetylcholine receptors are
responsible for the spastic paralysis in nematodes, which inhibits necessary movement and egg
laying (Martin & Robertson, 2010). Additionally, levamisole indirectly increases extracellular
dopamine concentrations via inhibition of the DAT, but also inhibits the norepinephrine
transporter (NET) (Hofmaier et al., 2014). The action of levamisole at these transporters (DAT
and NET) is 100- and 300-fold less potent than cocaine, and also has weak affinity for the
serotonin transporter (SERT). When administered orally, levamisole is readily absorbed via the
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gastrointestinal tract, metabolized via the liver, and excreted by the kidneys via urine (DEA,
2013). Though the metabolic processes responsible for the breakdown of levamisole are not
entirely clear (Engelmann & Richardson, 1986; Galtier, Coche, & Alvinerie, 1983; Hess, Ritke,
Broecker, Madea, & Musshoff, 2013; Kouassi, Caillé, Léry, Larivière, & Vézina, 1986), two of
the predominant metabolites are pemoline and aminorex.
Dissection and electrochemical detection techniques (Schmidt, Roznoski, & Ebert, 1990;
Spector, Munjal, & Schmidt, 1998) have detected significant regional and temporal peaks in
dopamine and serotonin concentrations following levamisole administration in male SpragueDawley rats (35 mg/kg; ip). Levamisole administration resulted in a complex regional and
temporal pattern of changes in dopamine (Figure 1; left panel) and serotonin (Figure 1; right
panel). Levamisole did not alter norepinephrine levels in most brain regions. However, there was
a slight and transient decrease in the cerebellum and midbrain. There was a large (p < 0.001) and
rapid time-dependent increase in levels of normetanephrine (NMN), a minor norepinephrine
metabolite, in all brain regions. The time-dependent effects of levamisole on dopamine were
especially complex and were regionally dependent. Notable peaks in dopamine were reached in
the striatum within 30 min and in the midbrain within 15 min following levamisole
administration. In contrast, peaks in hypothalamic serotonin concentrations were documented at
30, 60, and 120 min post-dose, and in midbrain serotonin concentrations at 120 min following a
single levamisole dose (35 mg/kg; ip; Spector et al., 1998).
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Figure 1. Regional changes in dopamine and serotonin concentrations following levamisole
administration (35 mg/kg; ip) in Sprague-Dawley rats (* = p < 0.05). Figure drawn from Tables
3 and 4 of Spector, Manjal, and Schmidt (1998).
Levamisole possesses limited stimulant-like properties, though the pharmacological
profile surrounding these effects has been left largely uninvestigated (Tallarida et al., 2014;
Tallarida, Tallarida, & Rawls, 2015). In recent years, limited experimental work has been carried
out regarding the pharmacokinetics of levamisole in nonhumans, although it has been shown to
have a half-life of approximately 3 to 4 hours in humans (DEA 2013; Luyckx et al., 1982). While
levamisole itself has not directly demonstrated abuse liability, its metabolite aminorex has been
shown to possess psychomotor stimulant properties that have been likened to those of
amphetamine (Hofmaier et al., 2014; Woolverton, Massey, Winger, Patrick, & Harris, 1994).
Indeed, the abuse liability of its synthetic counterpart (4-methylaminorex) has been repeatedly
showcased (e.g., Glennon & Misenheimer, 1990). It has been hypothesized that the metabolic
8

conversion of levamisole to aminorex is partially responsible for its use as an additive to cocaine.
Levamisole also has similar effects to cocaine regarding sodium channels. For example, it
has been clearly established that local anesthetics like lidocaine and cocaine are slow onoff sodium channel blockers and fast on-off potassium blockers (Bauman & DiDomenico, 2002).
Recently, Nowak, Rosay, Czégé and Fonta (2015) recorded local cortical field potentials and
reported that tetramisole reduced neuronal response amplitude in a dose-dependent manner and
decreased axonal conduction velocity. Levamisole had identical effects. Several control
experiments demonstrated that these actions of tetramisole were independent from this
compound acting on tissue non-specific alkaline phosphatase (TNAP). In
particular, tetramisole effects were not stereo-specific. The decrease of axonal conduction
velocity and the intracellular data suggested that these two imidazothiazoles block voltagedependent sodium channels. Thus, levamisole also produces local anesthetic effects that may be
comparable to those produced via cocaine administration, though these effects have not been
directly examined.
Complications related to levamisole-adulterated cocaine use. Although the adverse
side effects of levamisole administration have been known for some time (Symoens, Veys,
Mielants, & Pinals, 1978), the relatively recent trend of adding levamisole to cocaine has shed
new light on these effects in drug-using populations. An increasing number of reports of druginduced reactions related to levamisole have been documented, spanning a wide range of
conditions.
One of the most common and serious effects related to levamisole-tainted cocaine use is
agranulocytosis (i.e., agranulosis or granulopenia) (Buchanan, Vogel, & Eberhardt, 2010;
Caldwell, Graham, & Arnold, 2012; Czuchlewski et al., 2010; Hodinka et al., 1981; Muirhead &
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Eide, 2011; Thompson et al., 1980). Agranulocytosis, which has been referred to as a “chemical
form of AIDS”, is a condition in which the body fails to produce white blood cells, resulting in a
severe depletion and subsequent susceptibility to serious infection (VICE, 2014). Though overt
symptoms are often lacking, increased incidence of minor infections (e.g., urinary tract
infections) and pneumonia are often related to agranulocytosis. A number of common
prescription medications (e.g., NSAIDs, antiepileptics, and antibiotics) have been linked to
agranulocytosis. Another related condition affecting white blood cells is neutropenia, which
specifically affects neutrophils. Agranulocytosis and neutropenia have a similar
symptomatology, though the latter may also result in a number of less severe, more overt side
effects, such as fevers, ulcers, diarrhea and sore throat (NORD, 2015)
Vasculitis is another disturbing adverse effect of levamisole-tainted cocaine use (Abdul
Karim et al., 2013; James, Detz, Coralic, & Kanzaria, 2013; Tichauer, Fagan, & Goverman,
2014). In general, vasculitis is the rupturing and destruction of the blood vessels due to
inflammation. Unlike agranulocytosis, this condition presents with overt symptoms. One
particular form of vasculitis (cutaneous vasculopathy) specifically affects the small blood vessels
in the skin, resulting in large red, black, or purple skin discolorations (palpable purpura). Other
symptoms indicating vasculopathy are nose bleeds, hyptertension, and bloody stool.
The potential side effects of using levamsole-tainted cocaine range from mild to severe in
nature, with varying prognoses. These effects, combined with the well-established effects of
long-term cocaine use, make clear the case for studying the interaction between the two drugs
from a physiological and behavioral perspective.
Potentiation of drug effects. As previously noted, cocaine increases extracellular levels
of dopamine, norepinephrine, and serotonin in the brain by blocking plasma membrane
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monoamine transporters. Neuronal pathways involved in the production of these three
neurotransmitters are a reasonable place to look for targets underlying the potential interaction of
cocaine and levamisole. The addition of levamisole, a drug that also indirectly increases
extracellular dopamine concentrations via inhibition of these same transporters (i.e., DAT,
SERT, NET) creates a collectively greater inhibition of reuptake than either alone (i.e., additive
interaction). Moreover, the primary metabolite of levamisole, aminorex, directly increases
dopamine concentrations via reversal DAT and exerts amphetamine-like effects. This presents
the metaphorical “perfect storm” for a potential additive/supra-additive interaction.
Subsequently, dopamine reuptake is inhibited by both cocaine and levamisole binding to DAT.
Once levamisole begins conversion to aminorex, aminorex would induce an efflux of dopamine.
Thus, co-administration of cocaine and levamisole may result in potentiation of the already
potent psychomotor stimulant effects of cocaine and subsequently enhance the deleterious effects
of cocaine abuse (Follath, Burkart, & Schweizer, 1971; Mlczoch, Probst, Szeless, & Kaindi,
1980; Karch et al., 2014).
The number of reports of levamisole-adulterated cocaine continues to rise, and the
emergency reports and case studies are consistent with the early work demonstrating some of
levamisole’s adverse side effects (Abdul-Karim et al., 2013; Formeister, Falcone, & Mair, 2014;
Knowles et al., 2009; Michaud et al., 2014; Woolverton et al., 1994; Hofmaier et al., 2014). Due
to the physical and chemical properties of the drug (i.e., relatively odorless, white powder, high
melting point), in addition to its widespread availability in veterinary medicine, the culmination
of these characteristics lends itself to use as an adulterant or bulking agent in illicit drugs.
Analysis of drug interactions. The combined use of multiple drugs is an ever increasing
aspect of the human condition (Kantor, Rehm, Haas, Chan, & Giovannucci, 2015). However, it
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is rare that an emphasis is placed on this aspect of drug consumption when developing and
manufacturing novel compounds. Indeed, it is often only after a drug has been approved and
widely disseminated that some of the most important types of drug interactions have been
discovered (e.g., Chamsi-Pasha, 2001). Although an inarguably important aspect of
pharmacology, the study of drug interactions is rarely straightforward, even less so when the
dependent measures of interest are behavioral in nature.
One way of examining drug interactions is through isobolographic analysis (Loewe,
1953). Examining the interaction between two drugs in this way requires one have a common
effect against which to judge each individual drug’s efficacy. For example, ataxia is a popular
categorical outcome used to measure a given drug effect. The first step in conducting drug
interaction studies is to measure the relative potency of each drug alone. To this end, a range of
doses for both drug A and drug B are measured such that respective ED50 values are obtained.
The range of doses and their given effect is plotted along the axes of a graph, with a straight line
drawn between the ED50 for drug A on the abscissa, and drug B on the ordinate (see Figure 2).
This line now denotes the effect that would theoretically be achieved if both drugs enjoy a
simply additive interaction at each dose along the dose-effect function (i.e., linear isobole).
Though the terminology surrounding drug interactions has yet to be fully resolved (Wessinger,
1986; Woolverton, 2014), there are three broad types of drug interactions: infra-additivity,
simple additivity, and supra-additivity. In short, infra-additivity refers to the interaction effect of
two combined doses of drugs that is less than that predicted by simple additivity, and supraadditivity refers to any interaction that is greater than that predicted by simple additivity. The
description of these types of interactions is simplified using arithmetic terms. In a effectadditivity model (Woolverton, 2014) of simple additivity, 1 + 1 = 2, where the effects of drug A
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combine with the effects of drug B in an equal manner. In infra-additivity, 1 + 1 = 1.5, where the
effects of drug A combine with the effects of drug B in a manner that is less than the sum of the
parts. Finally, in supra-additivity, 1 + 1 = 5, where the effects of drug A combine with the effects
of drug B to produce a greater effect than the sum of its parts. The classic example of supraadditivity is the interaction between ethanol and chloral hydrate (Kaplan, Jain, Forney, &
Richards, 1969; Gessner & Cabana, 1970).

Figure 2. Graphical depiction of isobolographic analysis. The solid line (line of additivity) runs
through the ED50 value for Drug A and Drug B at the abscissa and ordinate, respectively. Dotted
lines represent 95% confidence intervals. Effect combinations that fall below the dotted range are
considered supra-additive interactions, while combinations above the dotted range are infraadditive.
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The method of conducting proper isobolographic analyses of drug interactions is more
resource intensive than that of traditional behavioral pharmacology study designs. That is, the
typical within-subject, small sample experimental designs are inconsistent with isobolographic
methodology, which ideally requires independent observations at often several dozen
combinations of doses. However, this challenge has not deterred behavioral researchers from
attempting to research drug combinations, especially employing the behavioral assays relevant to
assessing abuse liability (i.e., self-administration, drug discrimination, and dependence studies)
(see Harland et al., 1989; Woolverton, Wang, Vasterling, Carroll, & Tallarida, 2008).
Behavioral Models
Self-administration. Several assays are used to assess abuse liability and are described
in detail and compared elsewhere (see Ator & Griffiths, 2003; Yokel, 1987). In summary, drug
self-administration is considered to be the “gold standard” for assessing abuse liability.
Conditioned place preference (CPP) and drug discrimination (DD) procedures also provide
information relevant to the abuse liability of a compound. CPP, which involves primarily
classical conditioning processes, utilizes distinct environmental stimuli that have been repeatedly
paired with a drug stimulus to measure the potential rewarding effects of a drug. By measuring
the amount of time an animal spends in a drug-paired environment relative to a vehicle- or
control-paired environment, researchers are able to infer, relatively speaking, the potential
rewarding effects of a drug. In a similar manner, DD also relies on interoceptive drug stimuli to
aid in the measurement of drug effects. By training an animal to respond on a particular
operandum when one type of drug stimulus is present and on another when a different drug
stimulus is present, one is able to measure the similarity between a given drug’s subjective
effects (i.e., interoceptive stimulus condition) and the subjective effects of another (e.g., novel)
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compound. If that compound shares subjective effects with a drug that has known abuse
potential, then it is reasonable to assume that it does, as well. Additionally, one is able to infer
pharmacological effects of a drug based upon responding allocated to either a drug-appropriate
operandum or a vehicle-appropriate operandum. Although both procedures have their
advantages, examination of drug effects in both procedures relies exclusively upon responseindependent (i.e., experimenter-delivered) drug administration. Indeed, if one wishes to study the
effects of a compound on drug intake patterns, the only alternative is self-administration.
The primary advantages of self-administration stem from its demonstrated validity, as
well as its ability to provide meaningful, predictive data. Not only does the assay have strong
face validity, but the predictive validity has been demonstrated repeatedly with regard to known
drugs of abuse. For example, there is a high degree of concordance with regard to the results of
human-generated and animal-generated data (Horton, Potter, & Mead, 2013; Panlilio et al.,
2005), with a substantial majority of known drugs of abuse capable of maintaining the selfadministration behavior of animals (Yokel, 1987).
Jim Weeks, a cardiovascular pharmacologist at Upjohn Laboratories, developed a
procedure allowing for prolonged intravenous catheter placement in a freely moving rat (Weeks,
1962). Weeks, who at the time was exploring the effects of morphine, developed a method in
which rats were implanted with a jugular catheter attached to an infusion pump, which allowed
for near instantaneous reinforcement of operant responding through intravenous infusion of
morphine. This procedure revolutionized experimental design throughout the field of addiction
studies, and has since been widely adopted and advocated for by some of the top governmental
agencies across the globe in assessing the abuse liability of potential therapeutic compounds
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(Controlled Substance Staff (CSS), 2017; European Medicines Agency, 2006; ICH M3(R2),
2009).
Although self-administration procedures may utilize a variety of administration routes
(e.g., oral or intramuscular) and species (e.g., nonhuman primates, canines), the prototypical
animal model involves intravenous administration in rats. Cocaine is the typical training drug
used for a number of different reasons: 1) it is a robust reinforcer that readily establishes and
maintains behavior, 2) its effects on motor behavior allow for sessions of relatively short
duration, 3) animals trained to self-administer cocaine can easily be transitioned to other drugs of
abuse and continue to maintain self-administration, and 4) regulatory guidelines require the use
of a scheduled substance for submission as part of a new drug application (NDA) (Gauvin,
Dalton, & Baird, 2017).
Interaction effects. Cocaine self-administration is a direct demonstration of the
reinforcing effects of cocaine, as well as a product of behavioral history. As noted above, there
are several types of drug interactions, each of which are expressed differently in drug-taking
behavior. Due to the biphasic nature of the dose-effect curves produced by typical selfadministration procedures (Wise, 1987), supra-additivity can be observed in several ways. A
supra-additive interaction could take the form of an increased quantity of drug consumed and
include an increase in overall and local response rates. For example, when the dose-effect curve
shifts leftward (e.g., with agonist pretreatment), a dose located on the ascending limb would now
produce a greater effect. Dependent upon the location of the dose within the dose-effect curve, a
supra-additive interaction could also decrease drug intake and response rates. For example, a
dose located on the descending limb would result in decreased intake relative to baseline
conditions.
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Figure 3. Theoretical drug-interaction dose-effect curves. The self-administration of a given
positive control (drug of abuse) used as a maintenance drug (black filled circles, black line
graph) is plotted as a function of drug dose. The theoretical leftward shifts in the dose-effect
function that would be generated with a relevant agonist pretreatment (PTMT) (red solid circles,
red line graph; e.g., amphetamine pretreatment prior to cocaine self-administration), and with a
relevant antagonist pretreatment (solid blue circles, blue line graph; e.g. naloxone pretreatment
prior to hydrocodone self-administration) are also depicted. The theoretical rightward shift in the
dose-effect function induced by antagonist pretreatments may be limited by the direct effects on
response rates engendered by the antagonist if administered alone (cf. Young, 1986).
Thus, it is imperative to examine a range of doses and within-session response pattern data to
determine the true nature of a given drug’s effects upon the self-administration dose-effect curve.
Decreased intake following pretreatment with a compound could indicate any of the following
have occurred: 1) increased potency of the maintenance drug, 2) behavioral toxicity, 3) satiation,
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or 4) rate-limiting direct motoric effects. Through combined inspection of overall session data
(i.e., number of injections or total intake (mg/kg)) and within-session response patterns (e.g.,
cumulative record data), one is in particularly good position to determine the type of interaction
having occurred between the drugs in question. The complicated nature of shifts in dose-effect
curves produced using self-administration procedures has been documented (see Mello & Negus,
1996), but nonetheless many researchers often examine only one dose of a drug upon
consumption of another.
The clinical implications of either an infra- or supra-additive interaction with regard to
behavior between cocaine and another drug are vast. If a supra-additive interaction is observed, it
would suggest that levamisole alters the reinforcing efficacy of cocaine. Contrariwise, if an infraadditive interaction is observed, this could indicate that levamisole has reinforcing effects of its
own, which interfere with subsequent motivation for self-administration, or perhaps grossly
impair behavior.
Drug discrimination. Subjective effects are a crucial aspect of the drug taking
experience. The subjective effects of a drug refer to the covert, interoceptive stimuli generated
when a given dose of a drug is administered. In everyday terms, such effects refer to “how a drug
makes one feel”. One approach to studying the subjective effects of drugs is the drug
discrimination assay. Though several variations on the drug discrimination assay have been
developed for humans and nonhumans (Glennon & Young, 2011; Young, 1991), a foodreinforced, two-lever nonhuman operant procedure is the most commonly employed arrangement
in studying the subjective or interoceptive stimulus effects of a drug. In this arrangement, a fooddeprived organism (e.g., rat) is trained to respond on two separate operanda (e.g., right and left
levers). Training then progresses such that it is injected with a specific dose of a drug (e.g.,
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cocaine) and trained to respond on one lever to earn food. In separate training sessions, it
receives a specific dose of another drug (or saline) and is trained to respond on the alternate lever
to earn food. Once an animal is reliably responding on the appropriate lever after a given drug
administration (e.g., left lever—cocaine, right lever—saline) at some predetermined criteria, it
has learned the discrimination; the drug is a discriminative stimulus (SD) for responding on one
lever and a S-delta (SΔ) for responding on the other, while saline serves the opposite function.
Once animals have learned the discrimination according to some predetermined testing
criteria, a range of training drug doses are tested to yield a dose-effect curve. This dose-effect
curve encompasses a range of doses that produce no substitution (i.e., ≤ 20% stimulusappropriate responding), partial substitution (>20 but <80% stimulus-appropriate responding),
and full substitution (≥80% stimulus-appropriate responding) (Glennon & Young, 2011). Once a
dose-effect curve for the training drug has been established, another compound is then tested
along a range of doses to generate its own dose-effect curve, termed a cross-generalization
profile. Drugs that produce full substitution are then inferred to share some common stimulus
properties with that of the training drug. A number of different manipulations can then be carried
out (e.g., pretreatment with select antagonist/agonists) whose effects can be used to judge the
likely pharmacological mechanisms of action affecting the stimulus properties of the comparator
drug.
The phenomenon of partial substitution has sparked much debate in the field of
psychopharmacology (Stolerman, 1991). There have been two broad interpretations of the
subject, neither of which has been completely resolved. The first is that partial substitution
represents a breakdown of stimulus control, amounting to chance responding (Colpaert, 1987).
Others hold that partial substitution holds value as a concept, stating that a stimulus that partially
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substitutes for the training stimulus share some commonality, whether it be perceptual or
receptor-mediated in nature (Gauvin & Baird, 1999; Woods, Bertalmio, Young, Essman, &
Winger, 1988). Regardless, it is clear that partial substitution frequently occurs in drug
discrimination experiments. Several notable experiments (Gauvin et al., 1996; Gauvin, Carl,
Briscoe, Vallett, & Holloway, 1995; Gauvin, Criado, Moore, & Holloway, 1990; Gauvin,
Harland, Michaelis, & Holloway, 1989; Harland et al., 1989) have been conducted
demonstrating that drug doses that produce partial substitution in isolation can be combined to
produce full substitution in a way that is consistent with an effect-additive model of drug
interaction (Woolverton, 2014). The latter interpretations served as the basis for drug interaction
dose selections in the study that follows.
Interaction effects. While a primary use of the drug discrimination paradigm has been in
characterizing and elucidating the neurochemical and behavioral mechanisms underlying the
subjective effects of drugs, the interoceptive stimulus cues produced by concomitant
administration of two or more compounds have also been examined. When plotted as function of
dose, dose-effect curves for drug discrimination experiments are generally sigmoidal in nature,
whereby the degree of drug-appropriate responding increases as a function of dose. As with selfadministration dose-effect curves, shifts in drug discrimination dose-effect curves result from: 1)
potency shift, 2) behavioral sensitivity (i.e., tolerance or sensitization) (Bertalmio & Woods,
1987; Young & Sannerud, 1989), 3) direct neuropharmacological interactions at receptor
processes involved in the subjective effects of the training drug (i.e., agonist/antagonist
pretreatments; Colpaert, 1987; Li, Gerak, & France, 2011), 4) influence of behavioral variables
(Lotfizadeh, Zimmermann, Watkins, Edwards, & Poling, 2014; Sannerud & Griffiths, 1993;
Sannerud & Young, 1987), and 5) change in maximal drug efficacy (i.e., partial agonism)
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Examination of the cross-generalization profiles produced by a number of drugs against
that produced by the training drug represents a significant portion of the drug discrimination
literature. However, the interactive effects of a number of pretreatment drugs on subsequent
generalization have also been assessed using the assay. A majority of these drugs have been
targeted for their specific antagonist effects, with the goal of selectively altering or blocking the
interoceptive cue generated by administration of the training drug. These lines of research are of
particular interest for the development of pharmacotherapies for treatment of substance use
disorders.
Of relevance to the present experiments are those studies demonstrating the blockade or
enhancement of the cocaine cue. Many experiments have been carried out to examine the effects
of pretreatment compounds upon the cocaine cue. Generally, the focus of these studies has been
upon the various dopamine and serotonin receptor subtypes, in addition to the role that
norepinephrine plays in the neuropharmacological effects of cocaine. For example, pretreatment
with haloperidol, a nonselective D2 antagonist, dose-dependently decreases cocaine-appropriate
responding (Colpaert, Niemegeers, Janssen, 1978a). Generally, nicotinic agonists (Banks, 2014;
Mello & Newman, 2011) and various dopaminergic compounds (Callahan, de La Garza, &
Cunningham, 1997) have shown partial and full substitution for cocaine, respectively. Of
particular interest are those studies demonstrating nicotinic agonists do not substitute for cocaine,
but potentiate the effects of cocaine when administered concomitantly (Mello & Newman, 2011).
While the effects of cocaine on reuptake of dopamine are undoubtedly integral to the complex
cocaine stimulus, cocaine’s effects upon serotonin (Walsh & Cunningham, 1997) and
norepinephrine (Spealman, 1995) have also been shown to contribute to the complex
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interoceptive stimulus produced by cocaine administration, though the effects of these
manipulations are usually dose-dependent and partial in nature.
Another area of interest lies with the study of drugs that may potentiate or have supraadditive interactions regarding the discriminative effects of drugs of abuse (Gauvin et al., 1990;
Signs & Schechter, 1986; Young, Gabryszuk, & Glennon, 1998). Many studies have been
conducted concerning this matter, but few have employed the isobolographic analysis outlined
above (but see Harland et al., 1989; Lelas, Rowlett, & Spealman, 2001; Li, Koek, Rice, &
France, 2010; Massey & Woolverton, 1994; Rowlett, Spealman, & Platt, 2001). Hence, the
results of most studies are difficult to interpret.
Behavioral Literature
To date, no human studies have been conducted examining the cocaine-levamisole
interaction. However, two studies germane to the cocaine-levamisole interaction have been
carried out using animal models. Tallarida et al. (2014) sought to determine the effects of several
doses of levamisole and cocaine (alone and in combination) on the stereotypical movements and
CPP of planaria. Both cocaine and levamisole alone produced statistically significant
concentration-dependent increases in stereotyped movements. An isobolographic analysis was
used to reveal a supra-additive interaction regarding stereotypical movements, as measured by
the mean number of C-shaped movements. Cocaine produced CPP when administered in
isolation while levamisole did not. Statistically significant differences in preference scores were
observed relative to cocaine alone conditions when cocaine was administered in combination
with various concentrations of levamisole (0.1-1 µM). However, these differences in preference
scores were only observed for the lowest concentration of cocaine (0.001 µM).
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Tallarida, Tallarida, and Rawls (2015) expanded upon the work with planaria to examine
the effects of the cocaine-levamisole interaction on both locomotor activity and CPP in SpragueDawley rats. In the locomotor activity experiment, animals were injected (ip) with isotonic saline
solution, cocaine, levamisole, or a cocaine-levamisole combination, and activity counts were
measured across a 60-min session. Levamisole alone produced statistically significant increases
in locomotor activity (as measured by beam breaks) at 5 mg/kg, but not at 1 or 10 mg/kg when
compared to saline. Additionally, low doses of levamisole (0.1 mg/kg) increased cocaineinduced locomotor activity when combined with 10 mg/kg cocaine, but decreased activity in
combination with 30 mg/kg cocaine. Similar to the locomotor activity results, levamisole itself
resulted in CPP at only one dose (1 mg/kg; ip), located toward the middle of the dose range
tested. When administered concomitantly, previously inactive doses of levamisole and cocaine
produced CPP at doses that in isolation did not.
Given its prevalence as an adulterant in street drugs, and the increasing number of reports
of levamisole-induced adverse side effects, it is imperative that a full pharmacological and
behavioral profile of the drug be developed in order to understand, identify, and treat cases
related to the illegal drug use. To date, experimental work regarding the effects of levamisoletainted cocaine in the literature is scant, with behavioral research representing an extremely small
minority of that limited sample (Tallarida et al., 2014; Tallarida et al., 2015). Taken together, the
results of these drug interaction studies suggest that cocaine-levamisole combinations produce
effects greater than either drug administered in isolation. In other words, the effects of
concomitantly administered levamisole and cocaine are additive or synergistic, but only at a
select dose range. The potential for increased drug intake and modification of cocaine’s
subjective effects warrants further investigation. The present document describes two
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experiments aimed at characterizing the effects of levamisole on cocaine self-administration and
discrimination.
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CHAPTER II
EXPERIMENT 1: EFFECTS OF LEVAMISOLE ON COCAINE SELFADMINISTRATION IN SPRAGUE-DAWLEY RATS
Overview
Previous research (Tallarida et al., 2014; Tallarida et al., 2015) indicated that levamisole
sometimes increased the rewarding effects of cocaine as measured by CPP, but report of the
effects of levamisole on cocaine self-administration has not yet appeared. The most appropriate
way to assess this type of potential cocaine-levamisole interaction is to use a self-administration
procedure, whereby one is able to directly measure several aspects of drug-taking behavior. One
method of assessing the effects that one drug has upon the self-administration of another is by
pretreating animals with the relevant compound of interest, and measuring subsequent selfadministration behavior (Mello & Negus, 1996; National Institute on Drug Abuse, 2016). The
present study examined the acute effects of levamisole pretreatments on cocaine selfadministration by Sprague-Dawley rats.
Methods
Subjects. Thirty-two male Sprague-Dawley rats (Crl:SD) surgically implanted with
chronic indwelling jugular catheters (polyurethane with a micro-renethane tip; SAI Infusion
Technologies, Lake Villa, IL) were purchased from Charles River Laboratories (Portage, MI).
Catheters were inserted into the jugular vein and advanced to the atrium, while the exteriorized
portion exited a dorsal incision site at the midscapular area and was sutured and secured with a
wound clip. Each rat was fitted with a spandex jacket (Lomir Biomedical Inc., Notre-Dame-deI’île Perrot, Quebec, Canada) that was used to secure the catheter to a “quick-disconnect” jacket
adaptor (SAI Infusion Technologies) located on the dorsal surface of the rat. Rats were
approximately 4 months old (200-400g) and had previous experience (i.e., 30 days) self25

administering intravenous cocaine and a 3-day exposure to a novel CNS active compound under
identical behavioral contingencies used in this study (i.e., comparable drug histories). Animals
originally began cocaine training at 10 weeks of age. Following a two-week acclimation period,
the animals were initially food-deprived (see response acquisition below) but were allowed a 1015 gram per month weight gain to allow for normal growth throughout the duration of the study.
A 10-day washout period was imposed following transfer from the previous study and prior to
initiation of the present study.
Animals were pair-housed in polycarbonate caging with nonaromatic bedding (56 cm x
33 cm x 21 cm). To independently control food consumption and minimize the risk of catheter
damage during interactions, animals were separated by a perforated metal barrier (i.e., Buddy
Barrier™; Boggiano et al., 2008) that allowed for limited physical contact and interaction (i.e.,
visual, olfactory stimulation) between cohorts. Standard rodent bedding was changed and caging
sanitized weekly and animals were provided with both durable (Nyla rod) and nondurable
enrichment (Aspen wood blocks). Cages were housed within a temperature- (20-26ºC),
humidity- (30-70%), and air pressure-controlled vivarium on a 12:12 light/dark cycle
(fluorescent lights on at 0600). Lab Diet® Certified Rodent Diet #5002 (PMI Nutrition
International, Inc., Shoreview, MN) was provided throughout the study and animals were
allowed ad libitum access to water via bottles affixed to the outside of each cage. All
experimental procedures and husbandry practices described herein received prior approval of the
appropriate Animal Care and Use Committee and were conducted in full compliance with
current national and international law and in accordance with those methods described in the
Guide for the Care and Use of Laboratory Animals (National Research Council, 2011).
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Apparatus. Two-lever operant chambers (30.5 cm × 24.1 cm × 21.0 cm) (Med
Associates, St. Albans, VT), equipped with a swivel and tether system were used throughout the
experiment. Chambers (Med Associates, ENV-008CT) were equipped with both a food hopper
for pellet deliveries (response acquisition) and a single-speed (0.735 ml/min) syringe drive
infusion pump (Med Associates, PHM-100). A white noise generator connected to a single
external speaker was used to mask the sound of injection deliveries and any extraneous noise. 16
chambers were integrated and controlled through 16 interface modules (Med Associates, DIG716B) connected to an IBM-based computer system. Experimental events and data collection
were controlled through a Med-PC IV software system (Med Associates).
The injection volumes ranged from approximately 35 to 150 μL/injection. The injection
volume was determined by the duration of pump activation, which was controlled via computer
software (Med-PC IV, St. Albans, VT). The duration of pump activation was based on the
bodyweight of the animal, which was measured each day immediately prior to the session.
Infusion durations ranged from 6.9-10.1 sec in duration (M = 8.4; S.E.M. = 0.02). Previous
reports have demonstrated that injection onset and duration may be varied from immediate to
100 sec without significant effect on the acquisition or maintenance of self-administration,
progressive ratio breakpoints, reinstatement of drug-seeking behavior, or the assessment of the
reinforcing effects of intravenously administered drugs in general (Balster & Schuster, 1973;
Crombag, Ferrario, & Robinson, 2008; Kato, Wakasa, & Yanagita, 1987; Liu, Roberts, &
Morgan, 2005; Panlilio et al., 1998; Pickens, Dougherty, & Thompson, 1969; Woolverton &
Wang, 2004; Wakabayashi, Weiss, Pickup, & Robinson, 2010).
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Procedure
Catheter maintenance. Prior to each session, the animals’ catheters were flushed with
1.0 ml sterile saline (0.9% Normal Sterile Saline for Injection [USP]) to ensure smooth,
unrestricted flow into the catheter. During the flush, the animal was observed for any signs of
exterior or interior catheter leakage (e.g., the presence or development of a subdermal protrusion
near the catheter passage from midscapular to right jugular access to the heart). Following
session termination, animals were disconnected from the swivel/tether system and their catheters
subsequently locked with either 0.5 ml of a heparinized saline solution (30% heparin) or
heparinized dextrose solution (30% heparin), contingent upon whether the session immediately
preceded a break in the training/testing sequence (i.e., a day off).
Catheters, exteriorization sites, quick disconnect systems, and jackets were inspected and
animals were observed daily for signs of disease or distress. If catheters were found disconnected
or otherwise suspected to have been compromised (e.g., lack of responding during cocaine
maintenance sessions, observed swelling, unusual difficulty/ease during pre-session flush),
patency was tested using an acute dose of methohexital (0.5 mg/kg, Brevital™) delivered via
bolus injection through the catheter, and the animal was subsequently observed for prototypic
signs of acute administration of a rapid-onset, short-acting barbiturate (i.e., loss of righting reflex
and lack of muscle tone). If the catheter was declared non-patent, that animal was excluded from
further testing and was humanely euthanized in accordance with institutional standard operating
procedures approved by the IACUC. If a patency check was conducted on an animal and no
issue with the catheter was discovered, the animal was given that day off, and training was
restarted the following day.
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Response acquisition. Initially, rats were reduced to 85-95% of their individual freefeeding bodyweight to facilitate shaping of the initial lever press response. Upon initiation of a
session, a single retractable lever (left lever) extended into the chamber and a corresponding
stimulus lamp (located directly above the lever) and a house light were illuminated. Initially,
lever press responses were reinforced on a fixed-ratio 1 (FR 1) schedule of food reinforcement
(45 mg grain-based Dustless Precision Pellets®, Bio Serv, Flemington, NJ). Under this schedule,
each lever press immediately produced a food pellet. Sessions terminated after 50 reinforcer
deliveries or 30 min elapsed, whichever occurred first. Subsequent training sessions were
comparable, but progressed with a gradually increasing FR requirement implemented across
sessions (e.g., Day 1-FR 1, Day 2-FR 2, Day 3-FR 3...), which terminated with an FR 5 for food
deliveries for all rats.
Cocaine training. For the first cocaine training session, completion of the FR 5 response
requirement resulted in both a pellet and an intravenous infusion of cocaine (0.56
mg/kg/injection). Following access to both food and cocaine deliveries in this single session,
completing the FR 5 schedule in all subsequent training sessions resulted solely in the delivery of
a single bolus of cocaine (0.56 mg/kg/injection). Injection duration times and volumes were
based upon each individual animal’s daily pre-session body weight, such that each animal
received 0.56 mg/kg cocaine injections. Maintenance sessions terminated following delivery of
10 reinforcers (total daily dose of 5.6 mg/kg (iv)) or 60 min, whichever occurred first. Sessions
were limited to 10 injections to reduce the likelihood of tolerance developing to the reinforcing
effects of cocaine (Calipari, Ferris, & Jones, 2014; Emmett-Oglesby et al., 1993) over the initial
course of training and to prevent the possibility of overdose or toxicity (Gauvin, Guha, & Baird,
2015; Young & Herling, 1986). The 10 drug deliveries (total dose of 5.6 mg/kg) also provided a

29

total daily dose that was within the behaviorally active range for cocaine commonly used in drug
discrimination (e.g., Craft and Stratmann, 1996; Lamas, Negus, Gatch, & Mello, 1998) and
locomotor activity assays (e.g., Thomsen, 2014). During injections the stimulus lamp above the
lever flashed on and off for 0.5 s and the lever was retracted from the chamber. A 10-s timeout
followed each injection during which all lights were extinguished and the lever remained
retracted. Following the 10-s timeout, the stimulus and house lights were illuminated and the
lever inserted back into the chamber. Subsequent sessions were comparable but progressed with
a gradually increasing FR requirement implemented across sessions, terminating with an FR 10
for all rats. Training sessions were conducted 5 to 7 days each week, at approximately the same
time each day.
Cocaine testing. Each rat was required to maintain < 20% day-to-day variability in the
total number of injections earned for three consecutive days prior to each testing sequence. When
this criterion was met, a sequence comprising three consecutive daily, 1-hr sessions began.
Animals were injected (ip) with saline at a volume of 10 ml/kg 30 min prior to initiating the selfadministration session. Following the injection, each animal was placed into the darkened
chamber until 30 min had elapsed, at which point the test session was initiated. During test
sessions, rats were allowed unlimited access to self-administer a dose of cocaine (0-1.0
mg/kg/injection) on a FR 10 schedule of reinforcement for 1 hr for three consecutive days. Test
sequences always alternated with three cocaine maintenance sessions (i.e., Train-Train-TrainTEST-TEST-TEST-Train-Train-Train, etc.). Substitution tests for saline and the maintenance
dose (MD; 0.56 mg/kg/injection) for the cocaine alone condition were conducted for all animals
(n = 32). Every other dose of cocaine was tested with a random subgroup of animals (n = 6). The
same six animals were tested for each pretreatment condition for the maintenance dose (0.56
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mg/kg/injection). No levamisole dose higher than 10 mg/kg was administered due to the known
direct cardiotoxic effects of higher doses of levamisole and cocaine in the rat (Onuaguluchi and
Igbo, 1990). Accordingly, no cocaine dose higher than 0.56 mg/kg/injection was tested with
either levamisole pretreatment (1 or 10 mg/kg). Testing occurred in the following order: 1)
cocaine alone, 2) levamisole 1 mg/kg, and 3) levamisole 10mg/kg. All doses of cocaine (in all
three conditions) were tested in random order.
Levamisole testing. Training criteria to initiate levamisole testing was identical to that of
cocaine testing. Upon fulfillment of these criteria, test sequences were conducted consisting of
three consecutive, unlimited-access 1-hr sessions. Animals were injected (ip) with levamisole (1
or 10 mg/kg) at a volume of 10 ml/kg 30 min prior to initiating the self-administration session.
Animals were then placed into the chambers until 30 minutes had elapsed, at which point the test
session was initiated.
Drugs. Cocaine hydrochloride and levamisole hydrochloride were prepared weekly by
dissolving the salt in isotonic saline solution, which was filtered through a 0.22 μm
polyvinylidene fluoride (PVDF) filter. Doses were calculated and expressed as the base. The
standard weight of levamisole adulteration of seized cocaine samples has been reported to be 6%
by weight (Casale, Corbeil, Hays, 2008); that is, 1 g of cocaine contains 60 mg of levamisole.
The standard dose established by federal statute sentencing guidelines of the US Congress is 100
mg in a drug naïve user (United States Department of Justice (USDOJ), 2002) and up to 1 gram
in the experienced user (Chitwood, 1996). The 1 mg/kg levamisole dose is equivalent to 60 mg
in a 60 kg man following ingestion of 1 g of bulk illicit street product.
Data analysis. Differences between group mean data for drug intake of the maintenance
dose of cocaine (0.56 mg/kg/injection), the percentage of responses emitted within the first 15
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min for all conditions (i.e., “quarter-life” analysis), and inter-injection intervals for the
maintenance dose (0.56 mg/kg/injection) were analyzed for statistical significance using oneway repeated-measures ANOVA (Graphpad Prism 7, La Jolla, CA). Quarter-life analysis was
conducted using a modification of the measure originally described by Herrnstein and Morse
(1957), which excluded the first 3 min of each session to control for the initial “ramp up” in
responding observed within typical cocaine self-administration sessions (Willuhn, Wanat, Clark,
& Phillips, 2009).
Results
Table 1 summarizes the daily changes in the group total number of injections selfadministered (mean ± S.E.M.) during test sessions. Figure 4 shows for each cocaine dose and the
three pretreatment conditions (cocaine alone, 1, and 10 mg/kg levamisole) the group mean total
number of injections self-administered and total cocaine intake (mg/kg) across the three sessions
of each experimental condition (solid lines), and the number of injections during each 1-hr
session (bars). Pretreatment with 1 mg/kg levamisole decreased the mean number of injections of
cocaine at all doses except for 0.18 mg/kg/injection, and pretreatment with 10 mg/kg levamisole
further reduced the total number of injections at all doses of cocaine. During cocaine alone
testing, all doses of cocaine engendered extremely stable day-to-day intake over the three days of
access to cocaine (M = 32.19 injections; S.E.M. = 1.71), and responding was maintained across
the full tested dose range; even relatively low doses of cocaine (0.018-0.032 mg/kg/injection)
maintained stable day-to-day mean intakes across the 3-day tests. There were, however,
substantial differences across animals in performance at these low doses. Pretreatment with 1
mg/kg levamisole increased the overall day-to-day variability and decreased the number of
cocaine injections earned (M = 28.08 injections; S.E.M. = 2.12). Pretreatment with 10 mg/kg
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levamisole was associated with variable and unstable levels of self-administration (M = 15.24
injections; S.E.M. = 1.67.
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Table 1. Descriptive statistics of daily and 3-day averages of drug intake expressed as number of infusions during
unlimited access test sessions

Figure 4. Cocaine self-administration dose-effect curves. The group mean number of injections
administered in three consecutive daily, 1-hr unlimited access test sessions are plotted as a
function of the tested dose of cocaine (bars; mean ± 1 S.E.M.). The grand mean number of
injections for each test sequence (three days) is also shown as a line graph (solid lines). Each bar
represents the mean number of injections earned during the test sessions. The bars and means for
saline (SAL) and 0.56 mg/kg/injection cocaine were comprised of data gathered from all subjects
(n = 32). All other bars and means were comprised of data gathered from groups (n = 6).
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Figure 5. 3-day mean number of injections of the maintenance (MD; 0.56 mg/kg/injection)
cocaine dose across all three conditions. Levamisole (LVM) significantly and dose-dependently
decreased the mean number of injections when compared with the cocaine alone mean (1 mg/kg
LVM (p = .14), 10 mg/kg LVM (p = .007); F (2, 17), F = 2.18; 8.09).
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Figure 6. 3-day grand mean comparisons (n = 6) of total number of injections and total cocaine
intake (mg/kg) for the maintenance dose of cocaine (MD; 0.56 mg/kg/injection) for cocaine
alone 1 mg/kg and 10 mg/kg levamisole (LVM) pretreatment.
Although the total number of cocaine injections earned in a session is a meaningful
dependent variable, it provides no information about the temporal pattern of injections, which is
an important dimension of self-administration behavior (Young and Herling, 1986).
Accordingly, representative cumulative records for a rat administering saline and several doses
of cocaine (0.01, 0.1, and 0.56 mg/kg/injection (i.e., maintenance dose)) under conditions in
which no pretreatment, 1 and 10 mg/kg levamisole were administered are shown in Figures 7-9.
At 0.56 mg/kg/injection, responding persisted across the full 60-min sessions and without
substantial day-to-day variability, regardless of levamisole pretreatment condition.
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Figure 7A. Representative sample of cumulative records generated for unlimited-access test
sessions in the cocaine alone condition (saline). Session duration is shown on the abscissa and
the number of responses is shown on the ordinate.

38

Figure 7B. Representative sample of cumulative records generated for unlimited-access test
sessions in the cocaine alone condition (0.01 mg/kg/injection). Session duration is shown on the
abscissa and the number of responses is shown on the ordinate.
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Figure 7C. Representative sample of cumulative records generated for unlimited-access test
sessions in the cocaine alone condition (0.10 mg/kg/injection). Session duration is shown on the
abscissa and the number of responses is shown on the ordinate.
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Figure 7D. Representative sample of cumulative records generated for unlimited-access test
sessions in the cocaine alone condition (0.56 mg/kg/injection). Session duration is shown on the
abscissa and the number of responses is shown on the ordinate.
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Figure 7E. Representative sample of cumulative records generated for unlimited-access test
sessions in the cocaine alone condition (1.0 mg/kg/injection). Session duration is shown on the
abscissa and the number of responses is shown on the ordinate.
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Pretreatment with 1 mg/kg levamisole did not alter the within-session pattern of
responding, but was associated with a substantially less injections earned during each of the three
sessions of exposure.

Figure 8A. Representative samples of cumulative records generated for unlimited-access test
sessions in the 1 mg/kg levamisole (LVM) condition (saline). Session duration is shown on the
abscissa and the number of responses is shown on the ordinate.
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Figure 8B. Representative samples of cumulative records generated for unlimited-access test
sessions in the 1 mg/kg levamisole (LVM) condition (cocaine 0.01 mg/kg/injection). Session
duration is shown on the abscissa and the number of responses is shown on the ordinate.
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Figure 8C. Representative samples of cumulative records generated for unlimited-access test
sessions in the 1 mg/kg levamisole (LVM) condition (cocaine 0.10 mg/kg/injection). Session
duration is shown on the abscissa and the number of responses is shown on the ordinate.
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Figure 8D. Representative samples of cumulative records generated for unlimited-access test
sessions in the 1 mg/kg levamisole (LVM) condition (cocaine 0.56 mg/kg/injection). Session
duration is shown on the abscissa and the number of responses is shown on the ordinate.
The effects of pretreatment with 10 mg/kg levamisole appeared to be similar to those of 1
mg/kg pretreatment, but greater. Although levamisole pretreatment reduced the overall number
of responses (and injections) in a dose-dependent fashion, it did not substantially alter the
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temporal pattern of responding within or across sessions (see Figures 8 and 9). This effect is
evidenced by visual inspection of the cumulative records, the quarter-session analyses (Figure
11), and the inter-injection interval analysis for the three conditions (cocaine alone, 1 mg/kg
levamisole, and 10 mg/kg levamisole) (Figure 10).
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Figure 9A. Representative samples of cumulative records generated for unlimited-access test
sessions in the 10 mg/kg levamisole (LVM) condition (saline). Session duration is shown on the
abscissa and the number of responses is shown on the ordinate.
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Figure 9B. Representative samples of cumulative records generated for unlimited-access test
sessions in the 10 mg/kg levamisole (LVM) condition (cocaine 0.01 mg/kg/injection). Session
duration is shown on the abscissa and the number of responses is shown on the ordinate.
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Figure 9C. Representative samples of cumulative records generated for unlimited-access test
sessions in the 10 mg/kg levamisole (LVM) condition (cocaine 0.10 mg/kg/injection). Session
duration is shown on the abscissa and the number of responses is shown on the ordinate.
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Figure 9D. Representative samples of cumulative records generated for unlimited-access test
sessions in the 10 mg/kg levamisole (LVM) condition (cocaine 0.56 mg/kg/injection). Session
duration is shown on the abscissa and the number of responses is shown on the ordinate.
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Figure 10. Inter-injection intervals. The mean amount of time elapsed (minutes) between
successive injections earned throughout a maintenance dose (0.56 mg/kg/injection) test session is
displayed as a function of condition: 1) cocaine alone, 2) 1 mg/kg levamisole (LVM), and 3) 10
mg/kg LVM pretreatment.
The differences in the percentage of responses emitted within the first 15 min of a session during
cocaine and levamisole sessions were not statistically significant (1 mg/kg levamisole and 10
mg/kg levamisole (p > 0.10); F(2,17); F = 2.27). Additionally, differences in the mean interinjection intervals during maintenance dose test sessions between cocaine and levamisole
conditions were not statistically significant (1 mg/kg levamisole and 10 mg/kg levamisole (p >
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0.10); F(2, 7); F = 2.48), corroborating the trends observed in the cumulative records via visual
inspection.

Figure 11. Quarter-life analysis of responding during test sessions. The graph shows a withinsubject comparison for the maintenance dose across all three conditions (cocaine alone, 1 mg/kg
levamisole (LVM), and 10 mg/kg LVM pretreatment).
Discussion
As others have discussed (Feltenstein & See, 2008), the self-administration assay has
demonstrated robust validity and has provided an excellent tool for examining the
neuropharmacological and behavioral mechanisms contributing to the reinforcing effects of
drugs of abuse. Many species, including rats, reliably self-administer cocaine. As shown in
Figure 4 (above), in the present study the dose-effect relationship depicting the number of
cocaine injections as a function of cocaine dose was biphasic. Some authors refer to this pattern
as hormesis, which is defined as a dose-effect relationship in which there is a stimulatory
response at lower doses, but an inhibitory response at high doses, resulting in an inverted U53

shaped dose-effect curve (IUSDEC) (Baldi & Bucherelli, 2005; Calabrese and Baldwin, 2001a)
when number of injections is the dependent variable.
Calabrese and Baldwin (1999, 2000, 2001a,b) note that because of this general
phenomenon (i.e., hormesis), to examine the effects of only one self-administered dose would be
potentially misleading. Nonetheless, this strategy is often used to determine whether
pretreatment with a given compound alters subsequent self-administration of another. For
example, studies have shown that administration of the μ-opioid partial agonist, buprenorphine
(Mello, Mendelson, Bree, & Lukas 1990), the dopamine agonist, bromocriptine (Hubner &
Koob, 1990), and the NMDA antagonist, dextromethorphan (Pulvirenti, Balducci, & Koob,
1997), reduce intake of the maintenance dose of cocaine. Such findings are sometimes
mistakenly taken as evidence that the pretreatment drug is a candidate for consideration for use
as a pharmacotherapy for cocaine abuse.
Unfortunately, when number of drug self-administrations or total drug intake are the
primary dependent variables in a study, it is difficult to determine if a pretreatment drug actually
decreases the reinforcing effectiveness of another substance, such as cocaine. In the present
study, pretreatment with 10 mg/kg levamisole significantly reduced the mean number of cocaine
self-administrations at the maintenance (0.56 mg/kg/injection) dose when data were combined
across the three days of pretreatment with levamisole.
Figure 3 (above) presents hypothetical data showing the number of self-administrations
of cocaine when no pretreatment is given (black circles) and when pretreatment is arranged with
relevant agonist (blue circles) and antagonist (red circles) drugs. In this figure, the maintenance
dose is 0.56 mg/kg, which falls on the descending limb of the self-administration dose-effect
function. Administration of a relevant agonist would increase the relative potency of this
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maintenance dose and reduce responding (and cocaine self-administrations) at the maintenance
dose. However, administration of a relevant antagonist also would reduce responding at the 0.56
mg/kg maintenance dose. If these pretreatment drugs were tested at other doses of cocaine,
however, different results would be obtained. If levamisole was tested with only lower doses of
cocaine, one may conclude that levamisole potentiates the effects of cocaine and would not be
suitable as a potential pharmacotherapy. The dose-dependent differences in the extent and type
of effect that levamisole had on behavior are illustrated by the full dose-effect functions in
Figures 4 and 5.
Although pretreatment with both doses of levamisole generally reduced cocaine selfadministration in the present study, there were subtle but detectable differences in the effects of
levamisole pretreatment across cocaine doses and the interaction between the two drugs did not
conform to simple additivity/antagonist models of drug interaction. For example, at low cocaine
doses (0.01-0.032 mg/kg/injection), pretreatment with levamisole increased the number of
injections on day 1 (Figure 4), a pattern of responding that could be interpreted as an extinction
burst resulting from an antagonistic effect of levamisole (Morse, 1966; Amsel, 1967; Overmann
& Denny, 1974). Pretreatment with levamisole reduced cocaine self-administration on day 2 and
day 3 relative to control (i.e., no levamisole) levels, which is also consistent with an antagonistic
effect, because following the initial burst responding falls to a relative low level in extinction,
regardless of whether or not it is drug-induced. Given this analysis, the 3-day mean and daily
response measures for these doses of cocaine (0.01-0.32 mg/kg/injection) would be indicative of
levamisole interfering with the reinforcing effects of cocaine, as would be predicted by
antagonism and a subsequent rightward shift in dose-effect curve. But interpreting the effects of
pretreatment drugs on the ascending limb of the cocaine self-administration dose-response curve
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is fraught with difficulty, as other researchers have emphasized (Wise, 1987; Piazza, DerocheGamonent, Rouge-Pont, Le Moalet, 2000; Katz and Higgins, 2004), and for that reason
researchers often examine only a single cocaine dose, or only the descending limb of the doseresponse function (Wise, 1987; Ahmed & Koob, 2004).
Increases in responding observed across days at the peak of the dose-effect curve (0.056.18) suggest that 1 mg/kg levamisole may escalate intake over time, although the relatively small
range of doses at which this was observed and the short period of testing cannot confirm this
definitively. Such effects would be consistent with previous reports (Hofmaier et al., 2014;
Tallarida et al., 2015) regarding the nature of levamisole addition to illicit cocaine. Differences
in overall intake at these doses with 1 mg/kg levamisole pretreatment were insignificant.
However, drug intake for high doses of cocaine (0.32 and 0.56 mg/kg/injection) with 1 mg/kg
levamisole pretreatment was substantially lower than intake at other dose levels. These lower
intake levels may be a product of either behavioral toxicity or satiation, but summary selfadministration data cannot confirm either interpretation. Wilson and Schuster (1973)
summarized this phenomenon with regard to both monkeys and rats, and provided three reasons
why decreases in responding for a drug would be observed as unit dose is increased:
(1) the drug in a dose-dependent fashion may disrupt any ongoing behavior (2) at
higher dosages the drug may produce aversive effects e.g. stimulation, and these
may predominate over any increased reinforcing efficacy, or (3) perhaps drugrelated changes in neurotransmitter levels are occurring which in some manner
make the self-administration of additional quantities of the psychomotor
stimulants non-reinforcing. (p. 292)
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Overall session data (i.e., total number of infusions) are meaningful, but to fully
understand the effects of a pretreatment drug one must examine momentary changes in behavior,
which can be accomplished through the use of cumulative records, a once popular method for
examining the effects of a wide range of independent variables on responding (Lattal, 2004;
Poling, 1979). Figures 7A allow for comparison of response patterns for saline for all three
treatment conditions (cocaine alone, 1 and 10 mg/kg levamisole, respectively). Although dosedependent reductions in responding are evident with levamisole pretreatments, the response
patterns are generally similar across conditions. These dose-dependent differences are also
apparent at the lowest dose of cocaine tested. Figures 7-9B show cumulative record data for 0.01
mg/kg cocaine for all three treatments (cocaine alone, 1 and 10 mg/kg levamisole, respectively).
Figures 7B displays a response pattern typical of a drug stimulus failing to maintain selfadministration (0.01 mg/kg/injection cocaine). In contrast, the within- and between-session
response patterns for the low dose of cocaine (0.1 mg/kg/injection) show a high, stable rate of
responding across the entire session and across all three test days (Figures 7C). Figures 7-9C
showcase response patterns for 0.1 mg/kg/injection, the peak of the dose-effect function, for all
treatment conditions (cocaine alone, 1 and 10 mg/kg levamisole, respectively). Response patterns
for cocaine alone and 1 mg/kg levamisole for 0.1 mg/kg/injection are characteristic of an
effective, mid-dose reinforcer (i.e., stable, rapid responding throughout the sessions, with littleto-no post-reinforcement pause).
One limitation of this study was the use of non-naïve rats as subjects. Although a 10-day
washout period was instated following termination of the original source study for these animals,
this limited experimental history could have played a role in the subsequent self-administration
in the range of cocaine doses tested. For example, substitution testing with the Sponsor drug on
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the previous study failed to maintain self-administration behavior in any animal tested. That is,
all animals experienced conditions during which responding resulted in intravenous delivery of a
non-reinforcer. However, this additional “extinction” period (i.e., 3-day substitution test with a
non-reinforcer) was the same for all animals. Moreover, all animals also initially underwent 3day substitution tests with saline (i.e., a non-reinforcer), but cocaine self-administration was
readily re-acquired and maintained.
An additional limitation to the present study is inherent to the experimental design itself.
The present study was conducted using a standard preclinical self-administration study design,
whereby animals chosen for testing are selected at random from a group of animals that has
collectively met testing criteria. Each animal is repeatedly tested at varying doses (see Mello &
Negus, 1996), and subsequent performance is judged against a stable baseline of performance
established during intermediate 3-day training sequences. Thus, each animal could and did have
a slightly different testing history that precludes a within-subject assessment of behavior at all
doses tested, and which could impact the results of subsequent testing sessions. For example, it
has been shown that squirrel monkeys with a history of exposure to relatively higher doses of
cocaine self-administer lower doses more readily than in earlier tests when those same animals
did not have a history of high dose cocaine self-administration (Goldberg, 1973). However,
Young and Herling (1986) note that once contingent drug delivery is arranged for a given
behavior, the development and maintenance of behavior appears to be controlled by prevailing
access conditions, rather than by the conditions important in initially establishing the drug as a
reinforcer. Furthermore, all animals in this study had exposure to a range of both high and low
doses of cocaine (0.01-1 mg/kg/injection) and levamisole had comparable effects across animals.
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Thus, it seems unlikely that the abbreviated drug histories in the present study would have
influenced the present results, though it cannot be definitively excluded.
It is, of course, possible that levamisole at the doses tested generally decreases operant
behavior, regardless of reinforcer type. The lack of an extinction burst for the levamisole 10
mg/kg pretreatment on day 1 and the failure to observe a subsequent decrease in responding
across the remaining test sessions is likely a product of behavioral history coupled with direct
behavioral effects of levamisole on response rates. To properly tease apart the variables at play in
this situation would require an extended period of testing and a number of different controls
(e.g., food-maintained control group), neither of which were employed within the present design.
Cumulative records for the high dose of cocaine (0.56 mg/kg/injection) show diminished, yet
stable within- and between-session response patterns across the 3-day test sequence (Figures 71D). The intervals between injections (downward, diagonal blips of the pen) and the length of
the post-reinforcement pauses generally increase with relatively equal spacing in direct
proportion to the magnitude of the available dose of cocaine. Although comparatively little
responding occurred at these doses with levamisole pretreatments (Figures 8D and 9D),
responding is evenly distributed throughout the entire session, indicating that the higher doses of
cocaine are indeed serving to reinforce responding. Analysis of cumulative records suggests that
responding was spaced throughout the session in a manner consistent with an effective
reinforcer, rather than nonspecifically reduced due to behavioral toxicity.
Conclusion
Two prior studies using a CPP procedure demonstrated that under some conditions
levamisole can increase the rewarding effects of cocaine (Tallarida et al., 2014; Tallarida et al.,
2015). The present study explored whether similar effects would be observed under a cocaine
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self-administration procedure, in terms of increased self-administration of one or more doses of
cocaine. If such an effect were observed, it would seem to provide at least a partial accounting
for why producers often add levamisole to illicit cocaine. Pretreatment with two doses of
levamisole (1 and 10 mg/kg) never significantly increased cocaine self-administration. Instead,
pretreatment generally reduced cocaine self-administration at the maintenance dose (0.56
mg/kg/injection) and across a range of other doses (0.018-0.1; 0.32-0.56 mg/kg/injection). As
others have discussed at length (e.g., Balster & Lukas, 1985; Goldberg, Woods, & Schuster,
1969; Tallarida, Porreca, & Cowan, 1989; Tallarida, 2000), interpreting changes in drugmaintained responding induced by pretreatment with another substance poses conceptual
challenges. These discussions make it clear that proper interpretation requires researchers to
consider both the total number of responses emitted and moment-to-moment changes in
responding within test sessions (Mello & Negus, 1996; Roberts, Loh, & Vickers, 1989). The
present study examined both of these measures, and neither provided evidence that levamisole
pretreatment increased cocaine intake. Therefore, the present data do not support the hypothesis
that levamisole is added to illicit cocaine to increase the amount of cocaine self-administered by
street users in individual bouts of drug use.
To date, there are no published studies of the effects of levamisole on schedulecontrolled (e.g., FR) responding, and it is possible that levamisole at the doses tested generally
decreases operant behavior, regardless of reinforcer type. Such an action would be
incompatible with levamisole increasing cocaine self-administration under the conditions of the
present study. The effects of levamisole on responding controlled by reinforcers other than
cocaine are certainly worth investigating. Until such effects are known, a limitation of the
present study is that its findings may be confounded by nonspecific effects of levamisole.
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Another limitation is that levamisole pretreatment was evaluated, but human users would
administer levamisole simultaneously with cocaine, which might influence how the drugs
interact. Future studies examining the concomitant self-administration of cocaine-levamisole
combinations may yield a more complete and accurate picture of the effects of levamisole on
initiating and maintaining cocaine self-administration.
Although the metabolic processes responsible for the breakdown of levamisole are not
entirely clear (Hess et al., 2013), two of the predominant metabolites are pemoline and aminorex
(schedule IV and schedule I stimulants, respectively). Pemoline and aminorex are reported to
have amphetamine-like properties, hence adding levamisole to cocaine may over time increase
the intensity of the stimulant-like subjective effects produced by a single drug administration, as
well as the duration of those effects (Hofmaier et al., 2014). Such an action is likely to decrease
the amount of cocaine administered by a lab animal or a human in a single setting (Gold &
Balster, 1996), while increasing the relative reinforcing efficacy of a given dose of cocaine. But
it might well increase the likelihood that bouts of self-administration would be repeated, or the
perceived value (and worth) of the substance being administered. Either of these outcomes would
be desirable from the perspective of a drug dealer. Further research using other procedures (e.g.,
drug discrimination, demand curve analysis, reinstatement) to examine them is certainly merited.
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CHAPTER III
EXPERIMENT 2: ASSESSMENT OF THE SUBJECTIVE EFFECTS OF LEVAMISOLE
ALONE AND IN COMBINATION WITH COCAINE IN SPRAGUE-DAWLEY RATS
Overview
While measurement of drug-taking behavior is inarguably crucial to understanding the
behavioral profile of a given drug, the subjective or interoceptive stimulus effects of drug
administration comprise an important aspect of the drug-taking repertoire (Fischman & Foltin,
1991). Drug discrimination is one effective way to measure the subjective effects of drug
administration. Given that levamisole decreased intake of cocaine in the self-administration
experiment, it was a natural continuance of interest to determine whether the interoceptive or
subjective changes in cocaine by levamisole contributed to the change in the reinforcing efficacy
in the previous study.
Recently, the role of sex as a biological variable has enjoyed increasing popularity in the
world of preclinical research. This interest has largely been spurred by the recent changes for
NIH grant applicants (McCullough et al., 2014). This issue has garnered sufficient attention such
that recommendations have more recently affected preclinical abuse liability assessment. Indeed,
the most recent FDA Guidance document (CSS, 2017) has recommended the inclusion of male
and female subjects when conducting preclinical abuse liability assessments (but see Gauvin &
Zimmermann, 2017). Other investigators (e.g., Carroll & Anker, 2010; Craft, Kalivas, &
Stratmann, 1996) have demonstrated that sex can influence the effects that drugs of abuse have
upon behavior. Thus, it was also of interest to determine if sex influenced the cocaine-levamisole
interaction.
To this end, the cross-generalization profiles of levamisole alone and in combination with
cocaine were examined in males and females to determine if levamisole in isolation produces
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measurable discriminative stimulus effects similar to those of cocaine, or if cocaine-levamisole
combinations produce a more salient “cocaine-like” stimulus. Furthermore, earlier work
(Tallarida et al. 2014; 2015), including the previously detailed self-administration study, has
demonstrated interactions between cocaine and levamisole. Accordingly, the present study was
designed to assess: 1) the subjective effects of a range of cocaine doses, 2) the cross
generalization profiles between cocaine and levamisole, and 3) the relative changes in
discriminative stimulus effects engendered by concomitant administration of cocaine-levamisole.
While a cocaine-levamisole interaction has been demonstrated, it is unclear whether
levamisole itself or its active metabolites are responsible for the relative changes observed in the
CPP and self-administration studies. Hofmaier et al. (2014) noted that it is unlikely that
levamisole administration produces psychomotor stimulant effects. Rather, it is more likely that
either of the two centrally active metabolites of levamisole (pemoline and aminorex) is
responsible for any interaction when combined with cocaine. Thus, using the drug discrimination
paradigm to determine the time-course effects of levamisole alone and in combination with
cocaine is a useful way to assess this aspect of potential drug interaction. Finally, it was
previously noted that data are lacking on the non-specific effects of levamisole on operant
responding. Given that drug discrimination employs a food-maintained operant response (i.e.,
lever pressing), the present procedure provided an opportunity to assess whether levamisole or its
combination with cocaine have any rate-suppressing effects on food-maintained operant
responding.
Methods
Subjects. Sixteen experimentally naïve Sprague-Dawley rats (Crl:SD; 8 male, 8 female)
were purchased from Charles River Laboratories (Raleigh, NC). Rats were approximately 4-6
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weeks old (130-210g) at the initiation of the experiment. Following a 1-week acclimation period,
animals were food-deprived (see response acquisition below) but were allowed a 10-15 g per
month weight gain to allow for normal growth throughout the duration of the study.
Animals were pair-housed in polycarbonate caging with nonaromatic bedding (56 cm x
33 cm x 21 cm). To independently control food consumption, animals were separated by a
perforated metal barrier (i.e., Buddy Barrier™; Boggiano et al., 2008) that allowed for limited
physical contact and interaction (i.e., visual, olfactory stimulation) between cohorts. Standard
rodent bedding was changed and caging sanitized weekly and animals were provided with both
durable (Nyla rod) and nondurable enrichment (Aspen wood blocks). Cages were housed within
a temperature- (20-26ºC), humidity- (30-70%), and air pressure-controlled vivarium on a 12:12
light/dark cycle (fluorescent lights on at 0600). Lab Diet® Certified Rodent Diet #5002 (PMI
Nutrition International, Inc., Shoreview, MN) was provided throughout the study and animals
were allowed ad libitum access to water via bottles affixed to the outside of each cage. All
experimental procedures and husbandry practices described herein received prior approval by the
appropriate Animal Care and Use Committee, and were conducted in full compliance with
current national and international law and in accordance with those methods described in the
Guide for the Care and Use of Laboratory Animals (National Research Council, 2011).
Apparatus. Two-lever operant chambers (30.5 cm × 24.1 cm × 21.0 cm) (Med
Associates, St. Albans, VT) were used throughout the duration of the experiment. Chambers
(Med Associates, ENV-008CT) were equipped with both a food hopper for pellet deliveries. A
white noise generator connected to a single external speaker was used to mask any extraneous
noise. Sixteen chambers were integrated and controlled through sixteen interface modules (Med
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Associates, DIG-716B) connected to an IBM-based computer system. Experimental events and
data collection were controlled through a Med-PC IV software system (Med Associates).
Procedure
Response acquisition. During all sessions, both levers were extended into the chamber
and the corresponding stimulus lights illuminated. Sessions terminated after 50 reinforcer
deliveries or 30 min elapsed, whichever occurred first. Rats were initially shaped to press either
lever under a FR 1 schedule of food reinforcement, where each response immediately produced a
food pellet. Reinforcement was accompanied by the two stimulus lights located above each lever
flashing on and off for 0.5s during each reinforcer delivery. Following completion of the initial
response shaping session, responding on only one lever was reinforced. The lever on which the
least amount of responding occurred during the initial shaping session was the first to be trained
in isolation. Responding on the inappropriate lever reset the FR component, and required another
entire component be completed on the appropriate lever to earn reinforcement. After completing
a session (i.e., earning 50 reinforcers) on an FR-1, the lever that produced reinforcement was
alternated (e.g., Left, Right, Left, Right, etc.) daily. If the animal completed 50 reinforcers on
this lever, the FR requirement was increased by one and the lever producing reinforcement was
again alternated. This training sequence continued until the rat had completed an FR 3 on each
lever, at which point drug training commenced.
Drug training. Once drug training began, the reinforced lever was alternated in a
pseudo-random manner (e.g., L-R-R-L-R-R-L-L-R-L), repeating once every 10 days. This
random sequence was used to minimize the development of a lever preference during drug
training, and to bring responding solely under the control of the interoceptive stimuli. For each
animal, responding on a given lever was only reinforced after receiving an injection of cocaine,
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while responding on the other lever was only reinforced after receiving an injection of saline.
Responding on the inappropriate lever reset the FR component, and required another entire
component be completed on the appropriate lever to earn reinforcement. If an animal
successfully completed a session on a given FR component, the component was increased on an
individual basis to a terminal FR-10 schedule of reinforcement. The total number of drug and
saline days were balanced over the course of 30 days such that there was equal representation
with regard to exposure to the training stimuli. The following is a sample weekly sequence of
drug and saline training days: DSSDSSD. Training occurred 5-7 days each week at
approximately the same time each day.
Rats were injected with either saline or cocaine (10 mg/kg; ip) at a volume of 1 ml/kg 15
min prior to session initiation, and placed into the darkened chambers until the pre-session
injection interval (PSII) had elapsed, at which point both levers were extended into the chamber
and the corresponding stimulus lamps and a house light were illuminated. Drug training sessions
terminated after the delivery of 50 reinforcers or 30 min had elapsed, whichever occurred first.
Upon reaching the terminal FR 10 schedule on both levers, rats were required to complete a 5day, double-alternation sequence (e.g., DDSSD, SSDDS) to be considered for testing.
Additionally, rats were required to emit fewer than 18 total responses prior to the first reinforcer
delivery (FRF; see Colpaert, Niemegeers, & Janssen, 1978b) and have greater than 80%
stimulus-appropriate responding during the previous five sessions. If decrements in stimulus
control were observed on any intervening training sessions (i.e., >18 FRF or < 80% stimulusappropriate responding), an additional 2-day sequence of D-S or S-D was required before testing
recommenced.
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Testing. Testing commenced once rats had fulfilled the aforementioned criteria. Testing
sessions were identical to training sessions, with the exception that responding was reinforced on
either lever. That is, completion of 10 consecutive lever responses on either lever would result in
delivery of a reinforcer. Test sessions were alternated with training sessions in a simple sequence
(e.g., Drug—TEST—Saline—TEST—Drug—TEST). If during any interspersed training session
responding failed to meet the FRF or overall stimulus-appropriate response requirement (%), an
additional 2-day training sequence (e.g., S-D or D-S) was required to be completed before testing
recommenced. A total of 10 rats (5 males, 5 females) reached and maintained criteria for the
duration of the cocaine alone and levamisole alone (15- and 60-min PSII) conditions.
All test sessions consisted of a two injection (ip) procedure. For the cocaine alone doseeffect curve, rats were injected first with a dose of cocaine at 1 ml/kg in the lower right quadrant
of the abdomen, then with an additional injection of saline at 10 ml/kg in the lower left quadrant.
For levamisole tests, animals were first injected with saline at 1 ml/kg in the lower right quadrant,
and then with levamisole at 10 ml/kg in the lower left quadrant. For levamisole 60-min PSII,
levamisole was administered 60 min prior to session initiation, with an addition saline control
injection administered 15 min prior to session initiation. For cocaine-levamisole interaction tests,
rats were injected first with a dose of cocaine at 1 ml/kg in the lower right quadrant of the
abdomen, then with an additional injection of levamisole at 10 ml/kg 15 min prior to session
initiation. Saline and varying doses of cocaine (0.1-10 mg/kg) and levamisole (1-10 mg/kg) were
tested alone and in combination. The order of testing was as follows: cocaine alone, levamisole
(15-min PSII), levamisole (60-min PSII), and cocaine-levamisole interactions. All dose levels
were tested in random order with the exception of the interaction phase. No levamisole or
cocaine dose higher than 10 mg/kg was administered due to the known direct cardiotoxic effects
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of higher doses of levamisole and cocaine in the rat (Onuaguluchi and Igbo, 1990).
A subset of males (n = 4) and females (n = 4) were used for all cocaine-levamisole
combination studies for within-subject comparisons. Similar to the methods employed by Gauvin
et al. (1986) a limited range of dose combinations were tested, encompassing combinations
which in summation, would theoretically produce >80% cocaine-appropriate responding under
an effect-additivity model of drug interaction. Combination tests were not scheduled with
constituent doses of cocaine or levamisole that alone produced full substitution. When dose
combinations failed to engender cocaine-appropriate responding, dose levels were varied in an
effort to produce full generalization (>80% cocaine-appropriate responding). Cocaine and
levamisole doses up to 10 mg/kg were tested. The constituent levamisole dose was chosen at
random from the three highest doses that did not produce full substitution for cocaine. The first
cocaine dose to be tested in combination with that levamisole dose was the highest dose of
cocaine that did not produce full substitution. Once responding reached >80% cocaineappropriate responding with a given cocaine-levamisole combination, no higher cocaine dose
was tested in combination with that levamisole dose. Subsequently, decreasing cocaine doses
were tested until no substitution (i.e., <20% cocaine-appropriate responding) occurred in
combination with levamisole. Each dose combination was selected and tested based on an
individual animal’s generalization data. No dose of cocaine or levamisole that by itself produced
full substitution was tested in combination.
Drugs. Cocaine hydrochloride was prepared weekly by dissolving the salt in isotonic
saline solution, which was filtered through a 0.22 μm polyvinylidene fluoride (PVDF) filter. Due
to the lengthy stability of prepared levamisole solutions (Chiadmi et al., 2005), levamisole was
prepared in an identical manner to cocaine once prior to initiation of levamisole tests and again
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during the interaction tests, as needed. Doses of cocaine and levamisole were calculated and
expressed as the base. The standard weight of levamisole adulteration of seized cocaine samples
has been reported to be 6% by weight (Casale et al., 2008); that is, 1 g of cocaine contains 60 mg
of levamisole. The standard dose established by federal statute sentencing guidelines of the US
Congress is 100 mg in a drug naïve user (United States Department of Justice (USDOJ), 2002)
and up to 1 gram in the experienced user (Chitwood, 1996). The 1 mg/kg levamisole dose is
equivalent to 60 mg in a 60 kg man following ingestion of 1 g of bulk illicit street product.
Data analysis. The mean (± S.E.M ) percentage of drug-appropriate responding was
plotted as a function of dose for all three treatment conditions. Full substitution was defined as
≥80% of responses on the cocaine-appropriate lever, partial substitution as >20 but <80% of
responses on the cocaine-appropriate lever, and no substitution as <20% of responses on the
cocaine-appropriate lever. Linear regression was conducted to estimate the individual ED50
values for all relevant dose-effect curves (Graphpad Prism 7, La Jolla, CA). Doses included for
the linear regression were limited to the highest dose that produced no substitution and the
lowest dose that produced full substitution. Differences in the numbers of sessions to reach
testing criteria and effect-additivity predictions versus obtained values (see Woolverton, 2014)
were analyzed via an independent and paired samples t-tests, respectively. The mean (± S.E.M )
percent cocaine-appropriate responses response rates were expressed as responses per second
and plotted as a function of dose. Differences in percentage of cocaine-appropriate responding,
response rates, and FRF values were analyzed via two-way, mixed-model ANOVA, using
Dunnett’s multiple comparison test.
Results
The comparative number of training sessions required to meet criteria is shown in Figure
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12. The differences in the required number of training sessions to meet criteria for males and
females was not statistically significant (t = -1.8; p = .26).

Figure 12. Comparison of the number of training days required to meet testing criteria.
Table 2 is a summary of the estimated ED50 values for cocaine, levamisole, and cocainelevamisole dose combination tests. Figures 13 and 14 display the dose-effect curves for the range
of cocaine, levamisole (15- and 60-min PSII) and cocaine-levamisole combinations for each
individual animal.
Table 2. Individual estimated ED50 values for all three treatment conditions.
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Cocaine alone substituted for itself in a dose-dependent manner in both males and
females. The two-way mixed-model ANOVA showed no statistically significant effect of sex on
percentage of cocaine-appropriate responding (p = .46; F(1, 8) = .60), response rate (p = .39;
F(1, 8) = .81) or FRF values (p = .38; F(1, 8) = .89). There were statistically significant effects
of dose on percentage of cocaine-appropriate responding (p < .0001; F(9, 72) = 36.72) and
response rate (p < .05; F(9, 72) = 3.74), but not FRF values (p = .53; F(9, 72) = 1.38). Dunnett’s
multiple comparison test indicated significant at the 3.2 mg/kg dose level for the percentage of
cocaine-appropriate responding (p < .0001) and the 10 mg/kg dose level for response rate (p <
.05). The lowest doses of cocaine that produced either partial- or full-substitution produced
accompanying dose-dependent decreases in response rates.

Figure 13. Cocaine alone dose-effect curves for all three dependent measures for both male (n =
5; filled circles) and female (n = 5; open circles) rats. Error bars represent ± 1 S.E.M.
A representative within-subject (111F) cumulative record is presented below (Figure 14)
for three doses of cocaine which produced full (10 mg/kg), partial (5.6 mg/kg), or no substitution
(saline). The three panels display response patterns for an entire test session.
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Figure 14. Representative cumulative records for within-session responding for cocaine alone.
The top panels represent drug-appropriate responding while the bottom panels represent salineappropriate responses.
Cross-generalization profiles for levamisole were highly idiosyncratic. Levamisole fully
substituted for cocaine at the 15-min PSII for one animal (104M; male) and resulted in partial
substitution (24% cocaine-appropriate responding) for another (115F; female), though dosedependent increases in the percentage of drug-appropriate responding and decreases in response
rate at the group level were observed beginning at the 5.6 mg/kg dose. Levamisole (60-min PSII)
at 10 mg/kg produced full substitution in only one animal (104M).
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Figure 15. Levamisole alone dose-effect curves for all three dependent measures for both male
(n = 5; top panels) and female (n = 5; lower panels) rats. Filled and open squares represent 15and 60-min PSII treatment conditions, respectively. Error bars represent ± 1 S.E.M.
Levamisole administration using 15-min PSII resulted in dose-dependent decreases in
response rates. For the 15-min PSII, differences between male and female cocaine-appropriate
responding (p = .54; F(1, 8) = .41), response rates (p > 0.99; F(1, 8) = 0), and FRF values (p =
.48; F(1, 8) = .54) were not statistically significant at any dose tested. Levamisole administration
using the 60-min PSII resulted in dose-dependent decreases in response rates, but to a lesser
extent that the 15-min PSII condition. Like the 15-min PSII condition, differences between male
and female cocaine-appropriate responding (p = .93; F(1, 8) = .01), response rates (p = .68; F(1,
8) = .18), and FRF values (p = .62; F(1, 8) = .26) for the 60-min PSII condition were not
statistically significant at any dose tested. Differences in response rate for the 15- and 60-min
PSII conditions were statistically significant for males (p < .0001; F(5,20) = 12.08), with
significant differences between saline and the 5.6 (p < .05) and 10 mg/kg (p = .001) dose levels.
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Differences in response rate under the 15- and 60-min PSII conditions were statistically
significant for females (p < .0001; F(5,20) = 14.99), with significant differences between saline
and 10 mg/kg (p < .0010). Differences between 15- and 60-min PSII conditions on measures of
FRF were statistically significant for the 10 mg/kg levamisole dose in males (p = .02) but not
statistically significant for any dose tested in females (p = .23).
The conclusions supported by visual inspection of the data were corroborated by a twoway mixed-model ANOVA, which showed that differences between the three conditions on
cocaine appropriate responding (p < 0.001; F(5, 45) = 31.02) and response rates (p < 0. 001; F(5,
45) = 26.89) were statistically significant for 1 mg/kg cocaine and upward when compared to all
doses of levamisole for both PSII conditions, but not for any dose on the FRF measure (p = .78;
F(5, 45) = 0.49).
Drug combination tests. Differences between obtained and expected values assuming a
simple effect-additivity model of drug interaction were analyzed via a paired samples t-test,
showing an overall significant deviation from the model (t = 6.28; p < .0001) regardless of
levamisole dose. Overall, there was no difference between male and females subjects on
measures of percent cocaine-appropriate responding, response rates, or FRF values. Withinsubject data for drug combinations are presented below in Figures 17-25 for all three dependent
measures. Cocaine-levamisole combinations produced full substitution for cocaine, an effect that
was highly dependent upon the constituent levamisole dose. All cocaine-levamisole
combinations that produced partial or full substitution did so at consistently lower doses than for
either cocaine or levamisole constituent dose. Across all animals, levamisole was given in
combination with cocaine on 68 occasions. On 47 of those occasions (69%), a higher percentage
of cocaine-appropriate responses occurred than when the same dose of cocaine or levamisole
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was administered alone. This pattern was observed in 67, 67, 75, 62, and 71% of test sessions for
1, 1.8, 3.2, 5.6, and 10 mg/kg levamisole constituent doses, respectively. Figure 16 contains
representative cumulative record within-subject comparisons for three cocaine-levamisole test
combinations, one of which produced full substitution (LVM 5.6 and COC 3.2 mg/kg) while the
others resulted in partial substitution (LVM 10 and COC 1.8 mg/kg; LVM 10 and COC 3.2
mg/kg).

Figure 16. Representative cumulative records for within-session responding for cocainelevamisole combinations. The top panels represent drug-appropriate responding while the bottom
panels represent saline-appropriate responses.
For animal 103M (Figure 17), only 5.6 mg/kg levamisole combinations resulted in a ½
log unit leftward shift in the dose-effect curve, as well as dose-dependent decreases and increases
in response rate and FRF values, respectively. Two other doses tested (3.2 and 10 mg/kg LVM)
failed to substitute when combined cocaine, but 10 mg/kg levamisole combinations produced
dose-dependent decreases in responding and increases in FRF values.
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Figure 17. Dose-combination dose-effect curves for animal 103M.
Cocaine-levamisole combinations for animal 104M (Figure 18) dose-dependently
substituted for cocaine and did so at ½ log unit doses lower than cocaine alone. All three doses of
levamisole tested (1, 1.8, and 3.2 mg/kg) in combination with cocaine had nearly identical crossgeneralization profiles (percent cocaine-appropriate responding, response rate, and FRF). When
originally tested, levamisole alone produced dose full substitution at 5.6 mg/kg, indicating a ¼
log unit leftward shift from the levamisole alone curve.

Figure 18. Dose-combination dose-effect curves for animal 104M.
Animal 106M (Figure 19) demonstrated a ¼ log unit leftward shift in the dose-effect
curve for 5.6 mg/kg levamisole in combination with cocaine, producing full substitution at 3.2
mg/kg cocaine constituent dose, relative to the full substitution produced by the original 5.6
mg/kg cocaine alone dose. 3.2 and 10 mg/kg levamisole combinations resulted in only partial
substitution (24 and 50% cocaine-appropriate responding, respectively), with both doses
producing dose-dependent decreases in response rate and FRF as the constituent dose of cocaine
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increased.

Figure 19. Dose-combination dose-effect curves for animal 106M.
All three levamisole combination conditions (3.2, 5.6, and 10 mg/kg) produced leftward
shifts of the dose-effect curves relative to that of cocaine alone in animal 108M (Figure 20). 10
mg/kg levamisole combinations produced the greatest leftward shift of the dose-effect curve and
dose-dependent decreases in response rate. 3.2 and 5.6 mg/kg levamisole combinations also
shifted the dose-effect curve leftward, in a relatively equal manner. The differentiating dose for
these two levamisole combinations was the 3.2 mg/kg cocaine constituent dose, which produced
partial substitution (44 % cocaine-appropriate responding) when combined with 3.2, but not 5.6
mg/kg levamisole (14 % cocaine-appropriate responding). No appreciable effects were observed
upon the FRF measure for any levamisole combination tests.

Figure 20. Dose-combination dose-effect curves for animal 108M.
Interestingly, 108M demonstrated response alternation between vehicle- to drug- to vehicle-lever
switches during 5.6 mg/kg cocaine alone tests, though this pattern (Figure 21) did not persist for
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dose combination tests which resulted in partial substitution for this animal.
LVM 5.6 + COC 3.2

Figure 21. Cumulative record for 5.6 mg/kg cocaine alone test session for animal 108M. The top
panel represent drug-appropriate responding while the bottom panels represent saline-appropriate
responses.
The only levamisole combination condition dose that produced full substitution in animal
109F (Figure 22) was 10 mg/kg levamisole. Only one constituent cocaine dose showed increase
relative to cocaine alone conditions (1.8 mg/kg), which increased from 0 to 78% cocaineappropriate responding under the 10 mg/kg levamisole combination condition. Response rates
for the 10 mg/kg levamisole combinations were substantially lower than under all other
conditions, though no such effect was apparent with the other dose combinations. No appreciable
effect was observed upon the FRF measure.
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Figure 22. Dose-combination dose-effect curves for animal 109F.
Levamisole combinations increased cocaine-appropriate responding for all dose
combinations for animal 111F (Figure 23), except for the highest dose combination condition
tested (3.2 mg/kg COC with 10 mg/kg LVM). The levamisole combination dose-effect curves
were shifted leftward relative to the cocaine alone curve, with 3.2 mg/kg levamisole combination
condition producing the greatest effect next to 5.6 and 10 mg/kg, respectively. The 10 mg/kg
levamisole combination condition resulted in increased cocaine-appropriate responding up to the
1.8 mg/kg constituent cocaine dose, and then decreased when the cocaine dose was further
increased to 3.2 mg/kg. An accompanying decrease in response rate was also observed for this
dose combination. No appreciable effects were observed upon the FRF measure for any
levamisole combination tests.

Figure 23. Dose-combination dose-effect curves for animal 111F.
Levamisole combinations increased cocaine-appropriate responding for all dose
combinations for animal 114F (Figure 24), but only one levamisole combination resulted in full
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substitution (5.6 mg/kg LVM combination) at the highest constituent cocaine dose tested (3.2
mg/kg). The 5.6 mg/kg levamisole combination dose-effect curve was shifted ¼ log unit leftward
relative to the cocaine alone condition, with a previously ineffective cocaine dose (1.8 mg/kg)
producing partial substitution (63% cocaine-appropriate responding) when combined with 5.6
mg/kg levamisole. The other two levamisole combinations tested (3.2 and 10 mg/kg LVM)
produced only partial substitution (24 and 43% cocaine-appropriate responding, respectively) at
the highest constituent cocaine dose tested (3.2 mg/kg). A dose-dependent decrease in response
rates occurred for all three levamisole combination conditions, with the largest relative decrease
in response rate observed for the 10 mg/kg levamisole combination condition (relative to cocaine
alone). No appreciable effects on the FRF measure were observed for any levamisole
combination tests.

Figure 24. Dose-combination dose-effect curves for animal 114F.
Animal 115F (Figure 25) displayed a unique cross-generalization profile for levamisole
combination tests. Levamisole combinations produced ¾ and ½ log unit leftward shifts in the
dose-effect curves for 3.2 and 5.6 mg/kg levamisole combinations, respectively. 10 mg/kg
levamisole combination tests consistently produced full substitution in combination with all
constituent cocaine doses tested (0.1-1.8 mg/kg). Due to lack of an observed decrease in cocaineappropriate responding as doses were decreased, 10 mg/kg levamisole was again tested with
saline, identical to the levamisole alone condition (15-min PSII). This test also resulted in full
80

substitution (97% cocaine-appropriate responding). A substantial overall decrease in responding
occurred for all 10 mg/kg levamisole combination tests, with no appreciable effects on response
rate for the other two levamisole combination conditions. The FRF measure was unaffected
except for one constituent cocaine dose (3.2 mg/kg) under the 10 mg/kg levamisole combination
condition, as well as the 10 mg/kg levamisole and saline test, which showed large increases, past
the level of chance responding (i.e., >20 responses).

Figure 25. Dose-combination dose-effect curves for animal 115F.
Discussion
Studies examining the time-course effects of levamisole and its metabolites in humans
have been consistent in their findings. Both Hess et al. (2013) and Bertol et al. (2011) detected
peak levamisole and aminorex concentrations in human urine at 3 and 6-7 hr, respectively.
Additionally, Spector et al. (1998) have shown that acute levamisole administration in rats can
increase levels of dopamine, norepinephrine, and serotonin in several areas of the brain involved
in the subjective and reinforcing effects of many drugs of abuse. These two aspects of levamisole
administration and metabolism are thought to be responsible for its addition to illicitly
manufactured cocaine. However, to date there have been no studies directly examining the
subjective or reinforcing effects of concomitant cocaine-levamisole administration, nor have
there been any studies on the effects of these metabolic processes in the rat.
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Levamisole alone failed to substitute for cocaine in the majority of tests, although dosedependent increases in cocaine-appropriate responding were observed in those animals for which
substitution was observed. With the exception of one animal, the levamisole 60-min PSII
condition failed to produce a greater degree of cocaine-appropriate responding than did the 15min PSII condition, and generally failed to produce any substitution (i.e., <20% cocaineappropriate responding). Cross-generalization profiles for both levamisole conditions (15- and
60-mine PSIIs) were highly idiosyncratic in nature. With the exception of two animals (104M
and 115F), levamisole failed to even partially substitute for cocaine.
Several factors contribute to the characteristics of the cross-generalization profiles
generated in drug discrimination studies. The role of the training dose in drug discrimination has
been extensively documented in the literature (Negus & Banks, 2011; Stadler, Caul, & Barrett,
2011; Stolerman, Childs, Ford, & Grant, 2011), whereby animals trained to discriminate a
relatively low dose of training drug generalize to a varying dose range of the training stimulus at
lower doses than do their counterparts. Moreover, animals trained using a drug dose that is
systematically decreased over time will also generalize to the training stimulus at lower dose
than animals whose training dose is not titrated downward. Although all animals in the present
study received the same training drug dose (10 mg/kg cocaine or saline), the aspect of the
complex stimulus condition which was primarily responsible for its discriminative function was
likely idiosyncratic. This is evidenced in the individual differences between animals (see Figure
19) for the cocaine dose-effect curves, and most notably, in the levamisole alone crossgeneralization tests. This phenomenon has been demonstrated in the basic animal learning
literature, whereby animals have exhibited stimulus control by only one dimension of
a compound stimulus (Reynolds, 1961), or demonstrated multiply-controlled discriminative
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responses (Fink & Patton, 1953). Particularly relevant to the present discussion is Baron’s (1965)
summary of the literature:
[E]very stimulus property that happens to be correlated with contingencies of
reinforcement requiring differential responding acquires some degree of stimulus
control; when stimulus properties are presented in combination, their effects combine in
some manner to exert an even greater degree of control. (p. 75)
While the early behavioral literature was focused almost exclusively on the physical dimensions
of exteroceptive stimuli, this work has been extended to the use of interoceptive discriminative
stimuli. These idiosyncratic within-session response alternation patterns may suggest that the
specific stimulus condition that exerts control over behavior for a given rat changes throughout a
session. The phenomenon noted by Baron has also been highlighted within the behavioral
pharmacology literature (Colpaert et al., 1978b; Gauvin et al., 1989; Gauvin et al., 1995; Gauvin
et al., 1996). For example, Gauvin and colleagues have demonstrated that algebraic summation
of partial substitution effects, via concomitant administration of drug doses that in isolation
produce partial substitution, can in fact produce full substitution via the effect-additivity model
of drug interaction.
Differing experimental histories are also capable of influencing generalization test
results. However, the present study provided equivalent drug histories across animals, so this is
not a factor in the observed idiosyncratic cross-generalization profiles. Due to the nature of the
drug discrimination training and testing procedure, it is inevitable that some animals undergo a
different number of training sessions than others. Of course, it is possible that a slightly different
stimulus condition gained control of responding for animals that took longer to train than others,
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though there appears to be no discernable pattern with regard to the number of training sessions
required and proportion of cocaine-levamisole combinations which produced full substitution.
Behavioral toxicity and direct motoric effects of a drug combination can also alter the
outcome of generalization tests. For example, although cocaine-levamisole combinations tests
sometimes produced comparable levels of drug-appropriate responding for both 3.2 and 10
mg/kg levamisole combinations, response rate data assist in the interpretation of these
comparable outcomes on the percent cocaine-appropriate response measure. For example, 10
mg/kg levamisole with cocaine sometimes produced no interaction, or sometimes weaker
interaction than observed with 3.2 mg/kg levamisole with cocaine. This could be due to either a
lack of stimulus similarity between this condition and the cocaine administration, or due to a
general lack of responding. In some instances (e.g., 106M), upon examining response rates it is
apparent the rate of responding under 3.2 mg/kg levamisole with cocaine is comparable to that of
cocaine or levamisole alone, while rates for 10 mg/kg levamisole with cocaine display a notable
decrease. This is consistent the with 10 mg/kg levamisole alone rate data, and with the notion
that this dose, both in isolation and in combination with cocaine, has rate-limiting effects. This
could be due to influences upon motivating operations, direct motoric effects, or behavioral
toxicity.
In any case, the fact that levamisole often decreased response rates in a drug
discrimination paradigm provides support for the hypothesis that the effects observed in the
cocaine self-administration study, where levamisole generally reduced self-administration, were
in part attributable to nonspecific effects of levamisole on schedule-controlled responding. As
noted previously, such nonspecific effects make it difficult to ascertain how, or if, levamisole
affected the reinforcing value of cocaine.
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Drugs that produce effects that are sufficiently dissimilar to those of the training drug
evoke responding on the vehicle-appropriate lever. That is, responding defaults to the non-drug
lever even when a behaviorally-active dose of a different drug is administered. For example, it
has been repeatedly demonstrated that some classes of CNS-active drugs do not cross-generalize
to other classes of CNS-active drugs. Alternatively, drugs that produce generalization but do so
at a limited range of doses, may reach a ceiling effect with regard to drug-appropriate
responding. For example, such responding has been observed with three-choice drug
discrimination procedures, whereby percent drug-appropriate responding increases on a given
low-dose operanda until the stimulus effects no longer resemble those produced by that training
drug dose (i.e., inverted U-shaped dose-effect curve; Jones, Bigelow, & Preston, 1999).
Additionally, sufficiently high doses of a drug that cause non-specific receptor binding, motor
impairment, or behavioral toxicity may also result in stimulus effects that are dissimilar from that
of the training drug, which may evoke little-to-no responding, or responding on the vehicleappropriate lever.
The discriminative effects of CNS-active drugs are complex. As such, stimulus control is
not dependent upon one single receptor mechanism. While receptor binding characteristics of
drugs may show differences in relative affinities for particular receptors, all drugs also
demonstrate unbound affinities in in vitro assays. Stimulus control by cocaine, which relies upon
multiple neurotransmitter systems, is not unique. Administration of dopamine releasers (e.g.,
methamphetamine), reuptake inhibitors (e.g., cocaine), and selective dopamine D1 and D2
receptor agonists engender partial to full substitution for the discriminative stimulus effects of
cocaine (Baker et al., 1993; Callahan, Appel, & Cunningham, 1991; Costanza, Barber, & Terry,
2001; Filip & Przegaliński, 1997). Alternatively, D1 and D2 receptor antagonists block
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generalization to cocaine. Callahan et al. (1997) have concluded that dopamine D1 and D2
receptors in the mesocorticolimbic system are involved in modulating the discriminative
stimulus effects of psychostimulants, and that that nigrostiriatal dopamine system is not
primarily involved. It has also been demonstrated that while serotonin receptor compounds do
not substitute for cocaine, several serotonin receptor agonists (e.g., the indole derivative RU
24969, and the arylpiperazines MCPP, MK 212, TFMPP, and quipazine) differentially modulate
the discriminative stimulus effects of cocaine (Filip, Bubar, & Cunninham, 2006; Callahan &
Cunningham, 1995). Cocaine itself inhibits reuptake of dopamine, norepinephrine, and serotonin,
and the discriminative stimulus effects of cocaine are enhanced by monoamine reuptake
inhibitors (Cunningham & Callahan, 1991). Furthermore, it has even been suggested that the
histaminergic system may also modify the discriminative stimulus effects of both cocaine and
methamphetamine, through H1 and H3 receptors (Mori, Norita, Onodera, & Suzuki, 2002).
Clearly, the neuropharmacological profile of cocaine’s discriminative stimulus effects is
complex.
Although partial-substitution was observed repeatedly over the course of this study for all
three conditions, within-session response patterns were generally consistent. For example, most
animals (7 of 8) consistently demonstrated patterns of drug- to vehicle-lever response shifts
under cocaine alone conditions as the sessions progressed. Cocaine-levamisole dose-effect
curves were consistently shifted leftward relative to that of cocaine alone curves, but not
necessarily in a dose-dependent manner. This is not inconsistent with other types drug interaction
studies, which have shown increased effects relative to baseline, but that do not necessarily
demonstrate consistent effects (i.e., infra- or supra-additivity) across all combinations (e.g.,
Woolverton et al., 2008).
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The results of the present study are inconsistent with the hypothesis (Hofmaier et al.,
2014) that aminorex, rather than levamisole, is responsible for the potential interaction between
cocaine and use of levamisole as an adulterant. As noted by others (Hess et al., 2013; Bertol et
al., 2011), aminorex is not detected until several hours after levamisole administration.
Therefore, it is unlikely that the results obtained in the present study were due to the effects of
any behaviorally-active metabolites of levamisole. Furthermore, the results of the levamisole 60min PSII tests indicated that even less cocaine-appropriate responding occurred when
presumably levamisole might begin undergoing metabolic conversion to aminorex. However,
characterization of the metabolic profile of levamisole in the rat is lacking, and it is unclear at
what point aminorex is present after levamisole administration. The results in the present study
were obtained using a 15-min PSII, suggesting that the supra-additive interaction observed is due
to the effects of levamisole itself, rather than its metabolites.
No neurochemical measurement or analysis was conducted in the present study. That is,
all dependent measures were purely behavioral in nature. One limitation of the present study was
the exclusion of any antagonism tests, which could have potentially confirmed or denied the role
of dopaminergic activity in the ability of levamisole to substitute for cocaine. For example,
pretreatment with selective dopamine receptor antagonists could help elucidate which receptor
subtype may be primarily responsible for the discriminative stimulus effects of levamisole.
However, as noted earlier with regard to cocaine, drugs are complex stimuli with several
pharmacological mechanisms of action. Thus, several types of antagonist combination tests are
warranted to provide a more detailed picture of the neuropharmacological mechanisms
underlying the effects if levamisole. It is also worth noting that complete generalization alone
does not definitively prove that there is a comparable mechanism of action between two drugs.
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Rather, that the two drugs produce a similar stimulus effect (Glennon & Young, 2011). The
present results demonstrate that although levamisole alone may fail to reliably produce cocainelike effects in all animals, the interaction of these two compounds is generally additive, and more
commonly supra-additive. These results, in combination with that of the aforementioned selfadministration study, provide further evidence in support of the popular notion that levamisole is
added to cocaine in an attempt to potentiate or alter the reinforcing or subjective effects of
cocaine itself.
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CHAPTER IV
GENERAL DISCUSSION
Like many drugs, levamisole has the potential to have a profound impact upon behavior.
It remains unclear as to why drug manufacturers add levamisole to illicit cocaine. The two
theories as to why cocaine may be adulterated with levamisole deal with its physical similarity to
cocaine and the potential interaction with the effects of cocaine. Due to the reasons detailed
above (see Chapter 1), it would appear that the former is unlikely. The experiments described
herein clearly demonstrate that not only does levamisole produce measurable behavioral effects
in Sprague-Dawley rats, but that a supra-additive interaction with cocaine exists with regard to
these effects. Whether this dose additivity holds true with regard to all of cocaine’s effects in
humans needs to be investigated. It is clear that levamisole can have a negative impact upon the
physical condition of the human body, but the behavioral effects in humans remain to be
examined. Many experiments related to levamisole-adulterated cocaine cite the potentiation of
cocaine’s effects in humans as one of the main motives for its addition, but this has never been
reported in the literature and has yet to be examined experimentally.
The studies detailed above demonstrate that the behavioral effects of cocaine in rats can
be amplified when administered with levamisole, but the neuropharmacological and gross
physiological effects of their concomitant administration was not examined. The existing
literature demonstrates that other aspects of animal behavior (i.e., locomotor activity, CPP)
measured following concomitant cocaine-levamisole administration sometimes conform to a
supra-additive model of drug interaction. Thus, taken together with the results of the present
studies, it appears that this type of interaction extends to several aspects of behavior. Although
the assays used in the present experiments have demonstrated high degrees of validity, the
behavioral effects of cocaine-levamisole combinations in humans have yet to be directly
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reported. Therefore, it is unclear as to whether this type of interaction effect extends to human
behavior. Taken together, the results of these two studies enable us to provide some meaningful
statements regarding the behavioral effects of cocaine-levamisole combinations. Unfortunately,
the reasons for the addition of levamisole to illicit cocaine are still largely unclear, and much
research remains to be conducted to detect and prevent the untoward effects of this increasingly
widespread drug combination.
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